US20070249643A1 - Solid pharmaceutical dosage form - Google Patents
Solid pharmaceutical dosage form Download PDFInfo
- Publication number
- US20070249643A1 US20070249643A1 US11/773,185 US77318507A US2007249643A1 US 20070249643 A1 US20070249643 A1 US 20070249643A1 US 77318507 A US77318507 A US 77318507A US 2007249643 A1 US2007249643 A1 US 2007249643A1
- Authority
- US
- United States
- Prior art keywords
- dosage form
- soluble polymer
- water
- weight
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- the present invention is directed to a solid pharmaceutical dosage form comprising at least one HIV protease inhibitor, and a process for preparing the same.
- AIDS acquired immunodeficiency syndrome
- HTLV-III T-lymphocyte virus III
- LAV lymphadenopathy-associated virus
- ARV AIDS-related virus
- HIV-1 and HIV-2 two distinct families have been identified, i.e., HIV-1 and HIV-2.
- a measure of the potential usefulness of an oral dosage form of a pharmaceutical agent is the bioavailability observed after oral administration of the dosage form.
- Various factors can affect the bioavailability of a drug when administered orally. These factors include aqueous solubility, drug absorption throughout the gastrointestinal tract, dosage strength and first pass effect. Aqueous solubility is one of the most important of these factors.
- HIV protease inhibiting compounds typically are characterized by having poor aqueous solubility.
- a solid dosage form is usually preferred over a liquid dosage form.
- oral solid dosage forms of a drug provide a lower bioavailability than oral solutions of the drug.
- solid solution defines a system in a solid state wherein the drug is molecularly dispersed throughout a matrix such that the system is chemically and physically uniform or homogenous throughout.
- Solid solutions are preferred physical systems because the components therein readily form liquid solutions when contacted with a liquid medium such as gastric juice.
- the ease of dissolution may be attributed at least in part to the fact that the energy required for dissolution of the components from a solid solution is less than that required for the dissolution of the components from a crystalline or microcrystalline solid phase. If, however, the drug absorption in the gastrointestinal tract is slow the drug released from the solid solution may result in a high supersaturation and precipitate in the aqueous fluids of the gastrointestinal tract.
- the present invention provides a solid pharmaceutical dosage form comprising a solid dispersion of at least one HIV protease inhibitor in at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant.
- the pharmaceutically acceptable water-soluble polymer has a glass transition temperature (Tg) of at least about 50° C.
- solid dispersion defines a system in a solid state (as opposed to a liquid or gaseous state) comprising at least two components, wherein one component is dispersed evenly throughout the other component or components.
- the active ingredient or combination of active ingredients is dispersed in a matrix comprised of the pharmaceutically acceptable water-soluble polymer(s) and pharmaceutically acceptable surfactant(s).
- solid dispersion encompasses systems having small particles, typically of less than 1 ⁇ m in diameter, of one phase dispersed in another phase.
- a solid dispersion is a homogeneous, glassy system in which a solute is dissolved in a glassy solvent.
- Glassy solutions and solid solutions of HIV protease inhibitors are preferred physical systems. These systems do not contain any significant amounts of active ingredients in their crystalline or microcrystalline state, as evidenced by thermal analysis (DSC) or X-ray diffraction analysis (WAXS).
- the pharmaceutical dosage form is comprising from about 5 to about 30% by weight of the total dosage form (preferably from about 10 to about 25% by weight of the total dosage form) of an HIV protease inhibitor or a combination of HIV protease inhibitors, from about 50 to about 85% by weight of the total dosage form (preferably from about 60 to about 80% by weight of the total dosage form) of a water-soluble polymer (or any combination of such polymers), from about 2 to about 20% by weight of the total dosage form (preferably from about 3 to about 15% by weight of the total dosage form) of the surfactant (or combination of surfactants), and from about 0 to about 15% by weight of the total dosage form of additives.
- HIV protease inhibiting compounds suitable for use in the present invention include for example, but are not limited thereto:
- amprenavir VX-478
- DMP-323 DMP-450
- AG1343 noelfinavir
- ritonavir (Abbott Laboratories, Abbott Park, Ill., USA) is an HIV protease inhibitor which may be formulated into the dosage form of the invention.
- HIV protease inhibitor is ritonavir or a combination of ritonavir and at least one other HIV protease inhibitor, the dosage form showing a dose-adjusted AUC of ritonavir plasma concentration in dogs of at least about 9 ⁇ g.h/ml/100 mg.
- lopinavir (Abbott Laboratories, Abbott Park, Ill., USA) is an HIV protease inhibitor which may be formulated into the dosage form of the invention.
- lopinavir is an HIV protease inhibitor which may be formulated into the dosage form of the invention.
- This and other compounds, as well as methods for preparing same, are identified in U.S. Pat. No. 5,914,332, the disclosure of which is herein incorporated by reference.
- the present invention provides a dosage form wherein said HIV protease inhibitor is lopinavir or a combination of lopinavir and at least one other HIV protease inhibitor, the dosage form showing a dose-adjusted AUC of lopinavir plasma concentration in dogs of at least about 20 ⁇ g.h/ml/100 mg (preferably at least about 22.5 ⁇ g.h/ml/100 mg, most preferred at least about 35 ⁇ g.h/ml/100 mg).
- nelfinavir mesylate (marketed under the tradename Viracept by Agouron Pharmaceuticals, Inc. in La Jolla, Calif.) is an HIV protease inhibitor which may be formulated into the dosage form of the invention.
- the present invention provides a dosage form wherein said HIV protease inhibitor is a combination of ritonavir and lopinavir, the dosage form showing a dose-adjusted AUC of ritonavir plasma concentration in dogs of at least about 9 ⁇ g.h/ml/100 mg and a dose-adjusted AUC of lopinavir plasma concentration of at least about 20 ⁇ g.h/ml/100 mg (preferably at least about 22.5 ⁇ g.h/ml/100 mg, most preferred at least about 35 ⁇ g.h/ml/100 mg).
- AUC means “Area Under the Curve” and is used in its normal meaning, i.e. as the area under the plasma concentration-time curve from 0 to 24 hours, where the dosage form has been administered orally to dogs (beagle) under non-fasting conditions. “Non-fasting condition” means that the dogs receive a nutritionally balanced daily ration during the pre-test period and the whole test period.
- the AUC has units of concentration times time. Once the experimental concentration-time points have been determined, the AUC may conveniently be calculated, e.g. by a computer program or by the trapezoidal method. All AUC data herein were dose adjusted to the 100 mg dose level. For the purposes herein, the AUC is determined within a dose range where the AUC increases proportionally with dose. Administration of 50 mg ritonavir or 200 mg lopinavir, respectively, to dogs is considered suitable for determining the AUC values as used herein.
- the dosage forms according to the invention are characterized by an excellent stability and, in particular, exhibit high resistance against recrystallization or decomposition of the active ingredient(s).
- the dosage forms according to the present invention upon storage for 6 weeks at 40° C. and 75% humidity (e.g., when kept in high density polyethylene (HDPE) bottles without desiccant), the dosage forms according to the present invention usually do not exhibit any sign of crystallinity (as evidenced by DSC or WAXS analysis) and contain at least about 98% of the initial active ingredient content (as evidenced by HPLC analysis).
- the dosage form comprises at least one surfactant having an hydrophilic lipophilic balance (HLB) value of from about 4 to about 10, preferably from about 7 to about 9.
- HLB hydrophilic lipophilic balance
- the HLB system (Fiedler, H. B., Encyclopedia of Excipients, 5 th ed., Aulendorf: ECV-Editio-Cantor-Verlag (2002)) attributes numeric values to surfactants, with lipophilic substances receiving lower HLB values und hydrophilic substances receiving higher HLB values.
- Surfactants having an HLB value of from about 4 to about 10 suitable for use in the present invention include for example, but are not limited thereto:
- polyoxyethylene alkyl ethers e.g. polyoxyethylene (3) lauryl ether, polyoxyethylene (5) cetyl ether, polyoxyethylene (2) stearyl ether, polyoxyethylene (5) stearyl ether; polyoxyethylene alkylaryl ethers, e.g. polyoxyethylene (2) nonylphenyl ether, polyoxyethylene (3) nonylphenyl ether, polyoxyethylene (4) nonylphenyl ether, polyoxyethylene (3) octylphenyl ether;
- polyethylene glycol fatty acid esters e.g. PEG-200 monolaurate, PEG-200 dilaurate, PEG-300 dilaurate, PEG-400 dilaurate, PEG-300 distearate, PEG-300 dioleate;
- alkylene glycol fatty acid mono esters e.g. propylene glycol monolaurate (Lauroglycol®);
- sucrose fatty acid esters e.g. sucrose monostearate, sucrose distearate, sucrose monolaurate, sucrose dilaurate; or
- sorbitan fatty acid mono esters such as sorbitan mono laurate (Span® 20), sorbitan monooleate, sorbitan monopalmitate (Span® 40), or sorbitan stearate, or mixtures of one or more thereof.
- sorbitan mono fatty acid esters are preferred, with sorbitan mono laurate and sorbitan monopalmitate being particularly preferred.
- the dosage form may comprise additional pharmaceutically acceptable surfactants such as polyoxyethylene castor oil derivates, e.g. polyoxyethyleneglycerol triricinoleate or polyoxyl 35 castor oil (Cremophor® EL; BASF Corp.) or polyoxyethyleneglycerol oxystearate such as polyethylenglycol 40 hydrogenated castor oil (Cremophor® RH 40) or polyethylenglycol 60 hydrogenated castor oil (Cremophor® RH 60); or block copolymers of ethylene oxide and propylene oxide, also known as polyoxyethylene polyoxypropylene block copolymers or polyoxyethylene polypropyleneglycol, such as Poloxamer® 124, Poloxamer® 188, Poloxamer® 237, Poloxamer® 388, Poloxamer® 407 (BASF Wyandotte Corp.); or a mono fatty acid ester of polyoxyethylene castor oil derivates, e.g. polyoxyethyleneg
- polyoxyethylene (20) sorbitan monooleate Tween® 80
- polyoxyethylene (20) sorbitan monostearate Tween® 60
- polyoxyethylene (20) sorbitan monopalmitate Tween® 40
- polyoxyethylene (20) sorbitan monolaurate Tween® 20
- the surfactant having an HLB value of from about 4 to about 10 generally accounts for at least about 50% by weight, preferably at least about 60% by weight, of the total amount of surfactant used.
- the water-soluble polymer employed in the present invention has a Tg of at least about 50° C., preferably at least about 60° C., most preferred from about 80° C. to about 180° C.
- Tg values for the homopolymers may be taken from “Polymer Handbook”, 2nd Edition by J. Brandrup and E. H. Immergut, Editors, published by John Wiley & Sons, Inc., 1975.
- Water-soluble polymers having a Tg as defined above allow for the preparation of solid dispersions that are mechanically stable and, within ordinary temperature ranges, sufficiently temperature stable so that the solid dispersions may be used as dosage forms without further processing or be compacted to tablets with only a small amount of tableting aids.
- the water-soluble polymer comprised in the dosage form is a polymer that preferably has an apparent viscosity, when dissolved at 20° C. in an aqueous solution at 2% (w/v), of about 1 to about 5000 mPa ⁇ s. more preferably of about 1 to about 700 mPa ⁇ s, and most preferred of about 5 to about 100 mPa ⁇ s.
- Water-soluble polymers suitable for use in the present invention include for example, but are not limited thereto:
- N-vinyl lactams especially homopolymers and copolymers of N-vinyl lactams, especially homopolymers and copolymers of N-vinyl pyrrolidone, e.g. polyvinylpyrrolidone (PVP), copolymers of N-vinyl pyrrolidone and vinyl acetate or vinyl propionate,
- PVP polyvinylpyrrolidone
- cellulose esters and cellulose ethers in particular methylcellulose and ethylcellulose, hydroxyalkylcelluloses, in particular hydroxypropylcellulose, hydroxyalkylalkylcelluloses, in particular hydroxypropylmethylcellulose, cellulose phthalates or succinates, in particular cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose succinate or hydroxypropylmethylcellulose acetate succinate;
- high molecular polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide,
- polyacrylates and polymethacrylates such as methacrylic acid/ethyl acrylate copolymers, methacrylic acid/methyl methacrylate copolymers, butyl methacrylate/2-dimethylaminoethyl methacrylate copolymers, poly(hydroxyalkyl acrylates), poly(hydroxyalkyl methacrylates),
- vinyl acetate polymers such as copolymers of vinyl acetate and crotonic acid, partially hydrolyzed polyvinyl acetate (also referred to as partially saponified “polyvinyl alcohol”),
- oligo- and polysaccharides such as carrageenans, galactomannans and xanthan gum, or mixtures of one or more thereof.
- homopolymers or copolymers of N-vinyl pyrrolidone in particular a copolymer of N-vinyl pyrrolidone and vinyl acetate, are preferred.
- a particularly preferred polymer is a copolymer of about 60% by weight of the copolymer, N-vinyl pyrrolidone and about 40% by weight of the copolymer, vinyl acetate.
- the dosage forms of the invention may contain at least one conventional additive, such as flow regulators, lubricants, bulking agents (fillers) and disintegrants.
- the additive is contained in an amount of about 0.01 to about 15% by weight relative to the weight of the dosage form.
- the solid dosage forms according to the invention comprise the preparation of a solid solution of the HIV protease inhibitor or the combination of HIV protease inhibitors in a matrix of the water-soluble polymer and the surfactant, and shaping into the required tablet form.
- the solid solution product may be subdivided to granules, e.g. by grinding or milling, and the granules may subsequently be compacted to tablets.
- melt-extrusion Various techniques exist for preparing solid solutions including melt-extrusion, spray-drying and solution-evaporation with melt-extrusion being preferred.
- the melt-extrusion process comprises the steps of preparing a homogeneous melt of the HIV protease inhibitor or the combination of HIV protease inhibitors, the water-soluble polymer and the surfactant, and cooling the melt until it solidifies.
- Melting means a transition into a liquid or rubbery state in which it is possible for one component to get embedded homogeneously in the other. Typically, one component will melt and the other components will dissolve in the melt thus forming a solution. Melting usually involves heating above the softening point of the water-soluble polymer.
- the preparation of the melt can take place in a variety of ways. The mixing of the components can take place before, during or after the formation of the melt.
- the components can be mixed first and then melted or be simultaneously mixed and melted.
- the melt is homogenized in order to disperse the active ingredients efficiently.
- it may be convenient first to melt the water-soluble polymer and then to mix in and homogenize the active ingredients.
- the melt temperature is in the range of about 70 to about 250° C., preferably from about 80 to about 180° C., most preferred from about 100 to about 140° C.
- the active ingredients can be employed as such or as a solution or dispersion in a suitable solvent such as alcohols, aliphatic hydrocarbons or esters.
- a suitable solvent such as alcohols, aliphatic hydrocarbons or esters.
- Another solvent which can be used is liquid carbon dioxide. The solvent is removed, e.g. evaporated, upon preparation of the melt.
- additives may be included in the melt, for example flow regulators such as colloidal silica; lubricants, fillers, disintegrants, plasticizers, stabilizers such as antioxidants, light stabilizers, radical scavengers, stabilizers against microbial attack.
- extruders or kneaders include single screw extruders, intermeshing screw extruders or else multiscrew extruders, preferably twin screw extruders, which can be corotating or counterrotating and, optionally, be equipped with kneading disks.
- working temperatures will also be determined by the kind of extruder or the kind of configuration within the extruder that is used. Part of the energy needed to melt, mix and dissolve the components in the extruder can be provided by heating elements. However, the friction and shearing of the material in the extruder may also provide a substantial amount of energy to the mixture and aid in the formation of a homogeneous melt of the components.
- the melt ranges from pasty to viscous. Shaping of the extrudate conveniently is carried out by a calender with two counter-rotating rollers with mutually matching depressions on their surface. A broad range of tablet forms can be attained by using rollers with different forms of depressions. Alternatively, the extrudate is cut into pieces, either before (hot-cut) or after solidification (cold-cut).
- the resulting solid solution product is milled or ground to granules.
- the granules may then be compacted.
- Compacting means a process whereby a powder mass comprising the granules is densified under high pressure in order to obtain a compact with low porosity, e.g. a tablet. Compression of the powder mass is usually done in a tablet press, more specifically in a steel die between two moving punches.
- a solid dosage form of the invention comprises a combination of more than one HIV protease inhibitor (or a combination of an HIV protease inhibitor with one or more other active ingredients) it is of course possible to separately prepare solid solution products of the individual active ingredients and to blend the milled or ground products before compacting.
- At least one additive selected from flow regulators, disintegrants, bulking agents (fillers) and lubricants is preferably used in compacting the granules.
- Disintegrants promote a rapid disintegration of the compact in the stomach and keeps the granules which are liberated separate from one another.
- Suitable disintegrants are crosslinked polymers such as crosslinked polyvinyl pyrrolidone and crosslinked sodium carboxymethylcellulose.
- Suitable bulking agents also referred to as “fillers” are selected from lactose, calcium hydrogenphosphate, microcrystalline cellulose (Avicell®), silicates, in particular silicium dioxide, magnesium oxide, talc, potato or corn starch, isomalt, polyvinyl alcohol.
- Suitable flow regulators are selected from highly dispersed silica (Aerosil®), and animal or vegetable fats or waxes.
- a lubricant is preferably used in compacting the granules.
- Suitable lubricants are selected from polyethylene glycol (e.g., having a Mw of from 1000 to 6000), magnesium and calcium stearates, sodium stearyl fumarate, and the like.
- additives for example dyes such as azo dyes, organic or inorganic pigments such as aluminium oxide or titanium dioxide, or dyes of natural origin; stabilizers such as antioxidants, light stabilizers, radical scavengers, stabilizers against microbial attack.
- dyes such as azo dyes, organic or inorganic pigments such as aluminium oxide or titanium dioxide, or dyes of natural origin
- stabilizers such as antioxidants, light stabilizers, radical scavengers, stabilizers against microbial attack.
- Dosage forms according to the invention may be provided as dosage forms consisting of several layers, for example laminated or multilayer tablets. They can be in open or closed form. “Closed dosage forms” are those in which one layer is completely surrounded by at least one other layer. Multilayer forms have the advantage that two active ingredients which are incompatible with one another can be processed, or that the release characteristics of the active ingredient(s) can be controlled. For example, it is possible to provide an initial dose by including an active ingredient in one of the outer layers, and a maintenance dose by including the active ingredient in the inner layer(s). Multilayer tablets types may be produced by compressing two or more layers of granules. Alternatively, multilayer dosage forms may be produced by a process known as “coextrusion”.
- the process comprises preparation of at least two different melt compositions as explained above, and passing these molten compositions into a joint coextrusion die.
- the shape of the coextrusion die depends on the required drug form. For example, dies with a plain die gap, called slot dies, and dies with an annular slit are suitable.
- the dosage form In order to facilitate the intake of such a dosage form by a mammal, it is advantageous to give the dosage form an appropriate shape. Large tablets that can be swallowed comfortably are therefore preferably elongated rather than round in shape.
- a film coat on the tablet further contributes to the ease with which it can be swallowed.
- a film coat also improves taste and provides an elegant appearance.
- the film-coat may be an enteric coat.
- the film-coat usually includes a polymeric film-forming material such as hydroxypropyl methylcellulose, hydroxypropylcellulose, and acrylate or methacrylate copolymers.
- the film-coat may further comprise a plasticizer, e.g. polyethylene glycol, a surfactant, e.g. a Tween® type, and optionally a pigment, e.g. titanium dioxide or iron oxides.
- the film-coating may also comprise talc as anti-adhesive.
- the film coat usually accounts for less than about 5% by weight of the dosage form.
- the exact dose and frequency of administration depends on the particular condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art.
- compositions of the present invention for combined administration of ritonavir/lopinavir are shown below in Table 1, and the values are % by weight.
- Table 1 Ritonavir 18-22.5 4.17 4.17 Lopinavir in total 16.67 16.67 Copovidone (N-vinyl 65-75 71.16 70.12 pyrrolidone/vinyl acetate copolymer 60:40)
- Span 20 (Sorbitan 4-10 7.0 5.02 monolaurate) Cremophor RH40 0-10 — 3.02 (polyoxyethyleneglycerol oxystearate) Colloidal silica 0-3 1.0 1.0
- compositions of the invention for administration of ritonavir only are shown below in Table 2. The values are % by weight.
- Ritonavir 18-22.5 20.8 Lopinavir — — Copovidone (N-vinyl 60-75 63.15 pyrrolidone/vinyl acetate copolymer 60:40)
- Span 20 (Sorbitan 5-15 — monolaurate) in total Cremophor RH40 10.00 (polyoxyethyleneglycerol oxystearate) PEG 6000 0-8 5.00 Colloidal silica 0-3 1.04
- compositions are processed by melt extrusion.
- the resulting extrudates may be used as such or milled and compressed into tablets, preferably by the use of suitable tableting aids such as sodium stearyl fumarate, colloidal silica, lactose, isomalt, calcium silicate, and magnesium stearate, cellulose or calcium hydrogenphosphate.
- suitable tableting aids such as sodium stearyl fumarate, colloidal silica, lactose, isomalt, calcium silicate, and magnesium stearate, cellulose or calcium hydrogenphosphate.
- Dogs received a balanced diet with 27% fat and were permitted water ad libitum. Each dog received a 100 ⁇ g/kg subcutaneous dose of histamine approximately 30 minutes prior to dosing. A single dose corresponding to about 200 mg lopinavir, about 50 mg ritonavir, or about 200 mg lopinavir and about 50 mg ritonavir, respectively, was administered to each dog. The dose was followed by approximately 10 milliliters of water. Blood samples were obtained from each animal prior to dosing and 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after drug administration.
- the plasma was separated from the red cells by centrifugation and frozen ( ⁇ 30° C.) until analysis. Concentrations of HIV protease inhibitors were determined by reverse phase HPLC with low wavelength UV detection following liquid-liquid extraction of the plasma samples. The area under the curve (AUC) was calculated by the trapezoidal method over the time course of the study. Each dosage form was evaluated in a group containing 8 dogs; the values reported are averages for each group of dogs.
- Copovidone N-vinyl pyrrolidone/vinyl acetate copolymer 60:40; about 78.17 parts by weight
- ritonavir about 4.16 parts by weight
- lopinavir about 16.67 parts by weight
- colloidal silica about 1.0 part by weight
- the powdery mixture was then fed into a twin-screw extruder (screw diameter 18 mm) at a rate of about 2.0 kg/h and a melt temperature of about 133° C.
- the clear, fully transparent melt was fed to a calender with two counter-rotating rollers having mutually matching cavities on their surfaces. Tablets of 1080 mg were thus obtained.
- DSC and WAXS analysis did not reveal any evidence of crystalline drug material in the formulation.
- the dose-adjusted AUC in dogs was about 0.52 ⁇ g.h/ml/100 mg for ritonavir and about 4.54 ⁇ g.h/ml/100 mg for lopinavir.
- This example shows that solid solutions of HIV protease inhibitors without added surfactant yield a very poor bioavailability.
- Copovidone N-vinyl pyrrolidone/vinyl acetate copolymer 60:40; about 68.17 parts by weight
- Cremophor RH40 polyoxyethyleneglycerol oxystearate; about 10.00 parts by weight
- the resulting granules were mixed with ritonavir (about 4.17 parts by weight), lopinavir (about 16.67 parts by weight) and colloidal silica (about 1.00 parts by weight).
- the powdery mixture was then fed into a Leistritz Micro 18 twin-screw extruder at a rate of about 2.3 kg/h and a melt temperature of about 126° C.
- the extrudate was cut into pieces and allowed to solidify.
- the extruded pieces were milled using a high impact universal mill.
- the milled material (about 86.49 parts by weight) was blended in a bin blender with lactose monohydrate (about 6.00 parts by weight), crosslinked PVP (about 6.00 parts by weight), colloidal silica (about 1.00 part by weight) and magnesium stearate (about 0.51 parts by weight).
- the powdery blend was compressed to tablets of about 1378.0 mg on a Fette E 1 single punch tablet press.
- the tablets were then film-coated in a coating pan by spraying an aqueous dispersion for film coating (Opadry, available from Colorcon) at a temperature of about 60° C.
- the dose-adjusted AUC in dogs was about 0.60 ⁇ g.h/ml/100 mg for ritonavir and about 7.43 ⁇ g.h/ml/100 mg for lopinavir.
- This example shows that inclusion of a surfactant into solid solutions of HIV protease inhibitors improves the bioavailability attained.
- Copovidone N-vinyl pyrrolidone/vinyl acetate copolymer 60:40; about 853.8 parts by weight
- Span 20 Sorbitan monolaurate; about 83.9 parts by weight
- the resulting granules were mixed with ritonavir (about 50 parts by weight), lopinavir (about 200 parts by weight) and colloidal silica (about 12 parts by weight).
- the powdery mixture was then fed into a twin-screw extruder (screw diameter 18 mm) at a rate of about 2.1 kg/h and a melt temperature of about 119° C.
- the extrudate was fed to a calender with two counter-rotating rollers having mutually matching cavities on their surfaces. Tablets of about 1120 mg were thus obtained.
- the dose-adjusted AUC in dogs was about 10.88 ⁇ g.h/ml/100 mg for ritonavir and about 51.2 ⁇ g.h/ml/100 mg for lopinavir.
- This example shows that inclusion of a surfactant having an HLB of from about 4 to about 10 into solid solutions of HIV protease inhibitors markedly improves the bioavailability attained.
- Example 2 was repeated, however, the extrudate was cut into pieces and allowed to solidify.
- the extruded pieces were milled to a particle size of about 250 ⁇ m, using a high impact universal mill.
- the milled material was blended in a bin blender with sodium stearyl fumarate (about 12.3 parts by weight) and colloidal silica (about 8.0 parts by weight) for about 20 min.
- the powdery blend was compressed on a rotary tablet machine with 3 punches (6500 tablets/h).
- the tablets were then film-coated in a coating pan by spraying an aqueous dispersion for film coating (Opadry) at a temperature of about 60° C.
- Opadry aqueous dispersion for film coating
- the dose-adjusted AUC in dogs was about 14.24 ⁇ g.h/ml/100 mg for ritonavir and about 52.2 ⁇ g.h/ml/100 mg for lopinavir.
- Copovidone N-vinyl pyrrolidonelvinyl acetate copolymer 60:40; about 841.3 parts by weight
- Cremophor RH40 polyoxyethyleneglycerol oxystearate; about 36.2 parts by weight
- Span 20 Sorbitan monolaurate; about 60.2 parts by weight
- the resulting granules were mixed with ritonavir (about 50 parts by weight), lopinavir (about 200 parts by weight) and colloidal silica (about 12 parts by weight).
- the powdery mixture was then fed into a twin-screw extruder (screw diameter 18 mm) at a rate of about 2.1 kg/h and a melt temperature of about 114° C.
- the extrudate was fed to a calender with two counter-rotating rollers having mutually matching cavities on their surfaces. Tablets of 1120 mg were thus obtained.
- the dose-adjusted AUC in dogs was about 10.96 ⁇ g.h/ml/100 mg for ritonavir and about 46.5 ⁇ g.h/ml/100 mg for lopinavir.
- This example shows that a combination of a surfactant having an HLB of from about 4 to about 10 and a further surfactant can successfully be used.
- Example 4 was repeated, however, the extrudate was cut into pieces and allowed to solidify.
- the extruded pieces were milled to a particle size of about 250 ⁇ m, using a high impact universal mill.
- the milled material was blended in a bin blender with sodium stearylfumarate (about 13.9 parts by weight), colloidal silica (about 7.0 parts by weight), isomalt DC100 (about 159.4 parts by weight) and calcium silicate (about 7.0 parts by weight) for about 20 min.
- the blend was compressed and film-coated as described in example 1.
- the dose-adjusted AUC in dogs was about 10.38 ⁇ g.h/ml/100 mg for ritonavir and about 42.7 ⁇ g.h/ml/100 mg for lopinavir.
- Copovidone N-vinyl pyrrolidone/vinyl acetate copolymer 60:40; about 683.3 parts by weight
- Span 40 sorbitan monopalmitate; about 67.2 parts by weight
- the resulting granules were mixed with lopinavir (about 200 parts by weight) and colloidal silica (about 9.6 parts by weight).
- the powdery mixture was then fed into a twin-screw extruder (screw diameter 18 mm) at a rate of about 2.1 kg/h and a melt temperature of about 119° C. The extrudate was cut into pieces and allowed to solidify.
- the extruded pieces were milled using a high impact universal mill.
- the milled material was blended in a bin blender with sodium stearylfumarate (about 7.9 parts by weight), colloidal silica (about 11.3 parts by weight), isomalt DC100 (about 129.1 parts by weight) and sodium dodecyl sulfate (about 15.6 parts by weight).
- the blend was compressed and film-coated as described in example 1.
- Tablets corresponding to about 200 mg lopinavir were coadministered to dogs together with about 50 mg ritonavir.
- the dose-adjusted AUC of lopinavir was about 38.8 ⁇ g.h/ml/100 mg.
- Copovidone N-vinyl pyrrolidone/vinyl acetate copolymer 60:40; about 151.5 parts by weight
- Cremophor RH40 about 24 parts by weight
- PEG 6000 about 12 parts by weight
- the resulting granules were mixed with ritonavir (about 50 parts by weight) and colloidal silica (about 2.4 parts by weight).
- the powdery mixture was then fed into a twin-screw extruder and was melt-extruded. The extrudate was cut into pieces and allowed to solidify. The extruded pieces were milled using a high impact universal mill.
- the milled material was blended in a bin blender with colloidal silica (about 1.4 parts by weight), isomalt DC100 (about 31.9 parts by weight) and calcium silicate (about 4.2 parts by weight).
- colloidal silica about 1.4 parts by weight
- isomalt DC100 about 31.9 parts by weight
- calcium silicate about 4.2 parts by weight
- the dose-adjusted AUC in dogs was about 9.98 ⁇ g.h/ml/100 mg.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Description
- This application is a continuation of U.S. patent application Ser. No. 10/925,442, filed Aug. 25, 2004, now pending, which claims the benefit of U.S. Provisional Application Ser. No. 60/498,412, filed Aug. 28, 2003, both of which are incorporated herein by reference in their entireties.
- The present invention is directed to a solid pharmaceutical dosage form comprising at least one HIV protease inhibitor, and a process for preparing the same.
- The virus causing acquired immunodeficiency syndrome (AIDS) is known by different names, including T-lymphocyte virus III (HTLV-III) or lymphadenopathy-associated virus (LAV) or AIDS-related virus (ARV) or human immunodeficiency virus (HIV). Up until now, two distinct families have been identified, i.e., HIV-1 and HIV-2.
- One of the critical pathways in a retroviral life cycle is the processing of polyprotein precursors by aspartic protease. For instance with the HIV virus the gag-pol protein is processed by HIV protease. The correct processing of the precursor polyproteins by the aspartic protease is required for the assembly of infectious virions, thus making the aspartic protease an attractive target for antiviral therapy. In particular for HIV treatment, the HIV protease is an attractive target.
- A measure of the potential usefulness of an oral dosage form of a pharmaceutical agent is the bioavailability observed after oral administration of the dosage form. Various factors can affect the bioavailability of a drug when administered orally. These factors include aqueous solubility, drug absorption throughout the gastrointestinal tract, dosage strength and first pass effect. Aqueous solubility is one of the most important of these factors. Unfortunately, HIV protease inhibiting compounds typically are characterized by having poor aqueous solubility.
- For a variety of reasons, such as patient compliance and taste masking, a solid dosage form is usually preferred over a liquid dosage form. In most instances however, oral solid dosage forms of a drug provide a lower bioavailability than oral solutions of the drug.
- There have been attempts to improve the bioavailability provided by solid dosage forms by forming solid solutions of the drug. The term “solid solution” defines a system in a solid state wherein the drug is molecularly dispersed throughout a matrix such that the system is chemically and physically uniform or homogenous throughout. Solid solutions are preferred physical systems because the components therein readily form liquid solutions when contacted with a liquid medium such as gastric juice. The ease of dissolution may be attributed at least in part to the fact that the energy required for dissolution of the components from a solid solution is less than that required for the dissolution of the components from a crystalline or microcrystalline solid phase. If, however, the drug absorption in the gastrointestinal tract is slow the drug released from the solid solution may result in a high supersaturation and precipitate in the aqueous fluids of the gastrointestinal tract.
- There is a continuing need for the development of improved oral solid dosage forms for HIV protease inhibitors which have suitable oral bioavailability and stability and which do not necessitate high vehicle volumes.
- The present invention provides a solid pharmaceutical dosage form comprising a solid dispersion of at least one HIV protease inhibitor in at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant. In one embodiment, the pharmaceutically acceptable water-soluble polymer has a glass transition temperature (Tg) of at least about 50° C.
- The term “solid dispersion” defines a system in a solid state (as opposed to a liquid or gaseous state) comprising at least two components, wherein one component is dispersed evenly throughout the other component or components. For example, the active ingredient or combination of active ingredients is dispersed in a matrix comprised of the pharmaceutically acceptable water-soluble polymer(s) and pharmaceutically acceptable surfactant(s). The term “solid dispersion” encompasses systems having small particles, typically of less than 1 μm in diameter, of one phase dispersed in another phase. When said dispersion of the components is such that the system is chemically and physically uniform or homogenous throughout or consists of one phase (as defined in thermodynamics), such a solid dispersion will be called a “solid solution” or a “glassy solution”. A glassy solution is a homogeneous, glassy system in which a solute is dissolved in a glassy solvent. Glassy solutions and solid solutions of HIV protease inhibitors are preferred physical systems. These systems do not contain any significant amounts of active ingredients in their crystalline or microcrystalline state, as evidenced by thermal analysis (DSC) or X-ray diffraction analysis (WAXS).
- In one embodiment of the present invention, the pharmaceutical dosage form is comprising from about 5 to about 30% by weight of the total dosage form (preferably from about 10 to about 25% by weight of the total dosage form) of an HIV protease inhibitor or a combination of HIV protease inhibitors, from about 50 to about 85% by weight of the total dosage form (preferably from about 60 to about 80% by weight of the total dosage form) of a water-soluble polymer (or any combination of such polymers), from about 2 to about 20% by weight of the total dosage form (preferably from about 3 to about 15% by weight of the total dosage form) of the surfactant (or combination of surfactants), and from about 0 to about 15% by weight of the total dosage form of additives.
- HIV protease inhibiting compounds suitable for use in the present invention include for example, but are not limited thereto:
- (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3hydroxyhexane (ritonavir);
- (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane (ABT-378; lopinavir);
- N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridyl-methyl)-2(S)-N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);
- N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinoylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);
- 5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;
- 1-Naphthoxyacetyl-beta-methylthio-Ala-(2S,3S)3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4t-butylamide;
- 5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3amino-2-hydroxy-4-butanoyl-1, 3-thiazolidine-4-tbutylamide;
- [1S-[1R-(R-),2S*])-N1[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide;
- amprenavir (VX-478); DMP-323; DMP-450; AG1343 (nelfinavir);
- atazanavir (BMS 232,632);
- tipranavir;
- palinavir;
- TMC-114;
- RO033-4649;
- fosamprenavir (GW433908);
- P-1946;
- BMS 186,318; SC-55389a; BILA 1096 BS; and U-140690; or any combinations thereof.
- In one embodiment, ritonavir (Abbott Laboratories, Abbott Park, Ill., USA) is an HIV protease inhibitor which may be formulated into the dosage form of the invention. This and other compounds as well as methods for preparing same are disclosed in U.S. Pat. Nos. 5,542,206 and 5,648,497, the disclosures of which are herein incorporated by reference. In a further embodiment, the present invention provides a dosage form wherein said HIV protease inhibitor is ritonavir or a combination of ritonavir and at least one other HIV protease inhibitor, the dosage form showing a dose-adjusted AUC of ritonavir plasma concentration in dogs of at least about 9 μg.h/ml/100 mg.
- In another embodiment, lopinavir (Abbott Laboratories, Abbott Park, Ill., USA) is an HIV protease inhibitor which may be formulated into the dosage form of the invention. This and other compounds, as well as methods for preparing same, are identified in U.S. Pat. No. 5,914,332, the disclosure of which is herein incorporated by reference. In a further embodiment, the present invention provides a dosage form wherein said HIV protease inhibitor is lopinavir or a combination of lopinavir and at least one other HIV protease inhibitor, the dosage form showing a dose-adjusted AUC of lopinavir plasma concentration in dogs of at least about 20 μg.h/ml/100 mg (preferably at least about 22.5 μg.h/ml/100 mg, most preferred at least about 35 μg.h/ml/100 mg).
- In yet another embodiment, nelfinavir mesylate (marketed under the tradename Viracept by Agouron Pharmaceuticals, Inc. in La Jolla, Calif.) is an HIV protease inhibitor which may be formulated into the dosage form of the invention.
- The dosage forms of the present invention exhibit a release and absorption behaviour that is characterized by high attainable AUC, high attainable Cmax (maximum plasma concentration), and low Tmax (time to reach maximum plasma concentration).
- In still another embodiment, the present invention provides a dosage form wherein said HIV protease inhibitor is a combination of ritonavir and lopinavir, the dosage form showing a dose-adjusted AUC of ritonavir plasma concentration in dogs of at least about 9 μg.h/ml/100 mg and a dose-adjusted AUC of lopinavir plasma concentration of at least about 20 μg.h/ml/100 mg (preferably at least about 22.5 μg.h/ml/100 mg, most preferred at least about 35 μg.h/ml/100 mg).
- The term “AUC” means “Area Under the Curve” and is used in its normal meaning, i.e. as the area under the plasma concentration-time curve from 0 to 24 hours, where the dosage form has been administered orally to dogs (beagle) under non-fasting conditions. “Non-fasting condition” means that the dogs receive a nutritionally balanced daily ration during the pre-test period and the whole test period. The AUC has units of concentration times time. Once the experimental concentration-time points have been determined, the AUC may conveniently be calculated, e.g. by a computer program or by the trapezoidal method. All AUC data herein were dose adjusted to the 100 mg dose level. For the purposes herein, the AUC is determined within a dose range where the AUC increases proportionally with dose. Administration of 50 mg ritonavir or 200 mg lopinavir, respectively, to dogs is considered suitable for determining the AUC values as used herein.
- The dosage forms according to the invention are characterized by an excellent stability and, in particular, exhibit high resistance against recrystallization or decomposition of the active ingredient(s). Thus, upon storage for 6 weeks at 40° C. and 75% humidity (e.g., when kept in high density polyethylene (HDPE) bottles without desiccant), the dosage forms according to the present invention usually do not exhibit any sign of crystallinity (as evidenced by DSC or WAXS analysis) and contain at least about 98% of the initial active ingredient content (as evidenced by HPLC analysis).
- The term “pharmaceutically acceptable surfactant” as used herein refers to a pharmaceutically acceptable non-ionic surfactant. In one embodiment, the dosage form comprises at least one surfactant having an hydrophilic lipophilic balance (HLB) value of from about 4 to about 10, preferably from about 7 to about 9. The HLB system (Fiedler, H. B., Encyclopedia of Excipients, 5th ed., Aulendorf: ECV-Editio-Cantor-Verlag (2002)) attributes numeric values to surfactants, with lipophilic substances receiving lower HLB values und hydrophilic substances receiving higher HLB values. Surfactants having an HLB value of from about 4 to about 10 suitable for use in the present invention include for example, but are not limited thereto:
- polyoxyethylene alkyl ethers, e.g. polyoxyethylene (3) lauryl ether, polyoxyethylene (5) cetyl ether, polyoxyethylene (2) stearyl ether, polyoxyethylene (5) stearyl ether; polyoxyethylene alkylaryl ethers, e.g. polyoxyethylene (2) nonylphenyl ether, polyoxyethylene (3) nonylphenyl ether, polyoxyethylene (4) nonylphenyl ether, polyoxyethylene (3) octylphenyl ether;
- polyethylene glycol fatty acid esters, e.g. PEG-200 monolaurate, PEG-200 dilaurate, PEG-300 dilaurate, PEG-400 dilaurate, PEG-300 distearate, PEG-300 dioleate;
- alkylene glycol fatty acid mono esters, e.g. propylene glycol monolaurate (Lauroglycol®);
- sucrose fatty acid esters, e.g. sucrose monostearate, sucrose distearate, sucrose monolaurate, sucrose dilaurate; or
- sorbitan fatty acid mono esters such as sorbitan mono laurate (Span® 20), sorbitan monooleate, sorbitan monopalmitate (Span® 40), or sorbitan stearate, or mixtures of one or more thereof.
- The sorbitan mono fatty acid esters are preferred, with sorbitan mono laurate and sorbitan monopalmitate being particularly preferred.
- Besides the surfactant having an HLB value of from about 4 to about 10, the dosage form may comprise additional pharmaceutically acceptable surfactants such as polyoxyethylene castor oil derivates, e.g. polyoxyethyleneglycerol triricinoleate or polyoxyl 35 castor oil (Cremophor® EL; BASF Corp.) or polyoxyethyleneglycerol oxystearate such as polyethylenglycol 40 hydrogenated castor oil (Cremophor® RH 40) or polyethylenglycol 60 hydrogenated castor oil (Cremophor® RH 60); or block copolymers of ethylene oxide and propylene oxide, also known as polyoxyethylene polyoxypropylene block copolymers or polyoxyethylene polypropyleneglycol, such as Poloxamer® 124, Poloxamer® 188, Poloxamer® 237, Poloxamer® 388, Poloxamer® 407 (BASF Wyandotte Corp.); or a mono fatty acid ester of polyoxyethylene (20) sorbitan, e.g. polyoxyethylene (20) sorbitan monooleate (Tween® 80), polyoxyethylene (20) sorbitan monostearate (Tween® 60), polyoxyethylene (20) sorbitan monopalmitate (Tween® 40), polyoxyethylene (20) sorbitan monolaurate (Tween® 20).
- Where such additional surfactants are used, the surfactant having an HLB value of from about 4 to about 10 generally accounts for at least about 50% by weight, preferably at least about 60% by weight, of the total amount of surfactant used.
- The water-soluble polymer employed in the present invention has a Tg of at least about 50° C., preferably at least about 60° C., most preferred from about 80° C. to about 180° C. Methods for determining Tg values of the organic polymers are described in “Introduction to Physical Polymer Science”, 2nd Edition by L. H. Sperling, published by John Wiley & Sons, Inc., 1992. The Tg value can be calculated as the weighted sum of the Tg values for homopolymers derived from each of the individual monomers, i.e., that make up the polymer: Tg=ΣWiXi where W is the weight percent of monomer i in the organic polymer, and X is the Tg value for the homopolymer derived from monomer i. Tg values for the homopolymers may be taken from “Polymer Handbook”, 2nd Edition by J. Brandrup and E. H. Immergut, Editors, published by John Wiley & Sons, Inc., 1975.
- Water-soluble polymers having a Tg as defined above allow for the preparation of solid dispersions that are mechanically stable and, within ordinary temperature ranges, sufficiently temperature stable so that the solid dispersions may be used as dosage forms without further processing or be compacted to tablets with only a small amount of tableting aids.
- The water-soluble polymer comprised in the dosage form is a polymer that preferably has an apparent viscosity, when dissolved at 20° C. in an aqueous solution at 2% (w/v), of about 1 to about 5000 mPa·s. more preferably of about 1 to about 700 mPa·s, and most preferred of about 5 to about 100 mPa·s. Water-soluble polymers suitable for use in the present invention include for example, but are not limited thereto:
- homopolymers and copolymers of N-vinyl lactams, especially homopolymers and copolymers of N-vinyl pyrrolidone, e.g. polyvinylpyrrolidone (PVP), copolymers of N-vinyl pyrrolidone and vinyl acetate or vinyl propionate,
- cellulose esters and cellulose ethers, in particular methylcellulose and ethylcellulose, hydroxyalkylcelluloses, in particular hydroxypropylcellulose, hydroxyalkylalkylcelluloses, in particular hydroxypropylmethylcellulose, cellulose phthalates or succinates, in particular cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose succinate or hydroxypropylmethylcellulose acetate succinate;
- high molecular polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide,
- polyacrylates and polymethacrylates such as methacrylic acid/ethyl acrylate copolymers, methacrylic acid/methyl methacrylate copolymers, butyl methacrylate/2-dimethylaminoethyl methacrylate copolymers, poly(hydroxyalkyl acrylates), poly(hydroxyalkyl methacrylates),
- polyacrylamides,
- vinyl acetate polymers such as copolymers of vinyl acetate and crotonic acid, partially hydrolyzed polyvinyl acetate (also referred to as partially saponified “polyvinyl alcohol”),
- polyvinyl alcohol,
- oligo- and polysaccharides such as carrageenans, galactomannans and xanthan gum, or mixtures of one or more thereof.
- Of these, homopolymers or copolymers of N-vinyl pyrrolidone, in particular a copolymer of N-vinyl pyrrolidone and vinyl acetate, are preferred. A particularly preferred polymer is a copolymer of about 60% by weight of the copolymer, N-vinyl pyrrolidone and about 40% by weight of the copolymer, vinyl acetate.
- The dosage forms of the invention may contain at least one conventional additive, such as flow regulators, lubricants, bulking agents (fillers) and disintegrants. In general, the additive is contained in an amount of about 0.01 to about 15% by weight relative to the weight of the dosage form.
- Various methods can be used for manufacturing the solid dosage forms according to the invention. These methods comprise the preparation of a solid solution of the HIV protease inhibitor or the combination of HIV protease inhibitors in a matrix of the water-soluble polymer and the surfactant, and shaping into the required tablet form. Alternatively, the solid solution product may be subdivided to granules, e.g. by grinding or milling, and the granules may subsequently be compacted to tablets.
- Various techniques exist for preparing solid solutions including melt-extrusion, spray-drying and solution-evaporation with melt-extrusion being preferred.
- The melt-extrusion process comprises the steps of preparing a homogeneous melt of the HIV protease inhibitor or the combination of HIV protease inhibitors, the water-soluble polymer and the surfactant, and cooling the melt until it solidifies. “Melting” means a transition into a liquid or rubbery state in which it is possible for one component to get embedded homogeneously in the other. Typically, one component will melt and the other components will dissolve in the melt thus forming a solution. Melting usually involves heating above the softening point of the water-soluble polymer. The preparation of the melt can take place in a variety of ways. The mixing of the components can take place before, during or after the formation of the melt. For example, the components can be mixed first and then melted or be simultaneously mixed and melted. Usually, the melt is homogenized in order to disperse the active ingredients efficiently. Also, it may be convenient first to melt the water-soluble polymer and then to mix in and homogenize the active ingredients.
- Usually, the melt temperature is in the range of about 70 to about 250° C., preferably from about 80 to about 180° C., most preferred from about 100 to about 140° C.
- The active ingredients can be employed as such or as a solution or dispersion in a suitable solvent such as alcohols, aliphatic hydrocarbons or esters. Another solvent which can be used is liquid carbon dioxide. The solvent is removed, e.g. evaporated, upon preparation of the melt.
- Various additives may be included in the melt, for example flow regulators such as colloidal silica; lubricants, fillers, disintegrants, plasticizers, stabilizers such as antioxidants, light stabilizers, radical scavengers, stabilizers against microbial attack.
- The melting and/or mixing takes place in an apparatus customary for this purpose. Particularly suitable ones are extruders or kneaders. Suitable extruders include single screw extruders, intermeshing screw extruders or else multiscrew extruders, preferably twin screw extruders, which can be corotating or counterrotating and, optionally, be equipped with kneading disks. It will be appreciated that the working temperatures will also be determined by the kind of extruder or the kind of configuration within the extruder that is used. Part of the energy needed to melt, mix and dissolve the components in the extruder can be provided by heating elements. However, the friction and shearing of the material in the extruder may also provide a substantial amount of energy to the mixture and aid in the formation of a homogeneous melt of the components.
- The melt ranges from pasty to viscous. Shaping of the extrudate conveniently is carried out by a calender with two counter-rotating rollers with mutually matching depressions on their surface. A broad range of tablet forms can be attained by using rollers with different forms of depressions. Alternatively, the extrudate is cut into pieces, either before (hot-cut) or after solidification (cold-cut).
- Optionally, the resulting solid solution product is milled or ground to granules. The granules may then be compacted. Compacting means a process whereby a powder mass comprising the granules is densified under high pressure in order to obtain a compact with low porosity, e.g. a tablet. Compression of the powder mass is usually done in a tablet press, more specifically in a steel die between two moving punches. Where a solid dosage form of the invention comprises a combination of more than one HIV protease inhibitor (or a combination of an HIV protease inhibitor with one or more other active ingredients) it is of course possible to separately prepare solid solution products of the individual active ingredients and to blend the milled or ground products before compacting.
- At least one additive selected from flow regulators, disintegrants, bulking agents (fillers) and lubricants is preferably used in compacting the granules. Disintegrants promote a rapid disintegration of the compact in the stomach and keeps the granules which are liberated separate from one another. Suitable disintegrants are crosslinked polymers such as crosslinked polyvinyl pyrrolidone and crosslinked sodium carboxymethylcellulose. Suitable bulking agents (also referred to as “fillers”) are selected from lactose, calcium hydrogenphosphate, microcrystalline cellulose (Avicell®), silicates, in particular silicium dioxide, magnesium oxide, talc, potato or corn starch, isomalt, polyvinyl alcohol.
- Suitable flow regulators are selected from highly dispersed silica (Aerosil®), and animal or vegetable fats or waxes.
- A lubricant is preferably used in compacting the granules. Suitable lubricants are selected from polyethylene glycol (e.g., having a Mw of from 1000 to 6000), magnesium and calcium stearates, sodium stearyl fumarate, and the like.
- Various other additives may be used, for example dyes such as azo dyes, organic or inorganic pigments such as aluminium oxide or titanium dioxide, or dyes of natural origin; stabilizers such as antioxidants, light stabilizers, radical scavengers, stabilizers against microbial attack.
- Dosage forms according to the invention may be provided as dosage forms consisting of several layers, for example laminated or multilayer tablets. They can be in open or closed form. “Closed dosage forms” are those in which one layer is completely surrounded by at least one other layer. Multilayer forms have the advantage that two active ingredients which are incompatible with one another can be processed, or that the release characteristics of the active ingredient(s) can be controlled. For example, it is possible to provide an initial dose by including an active ingredient in one of the outer layers, and a maintenance dose by including the active ingredient in the inner layer(s). Multilayer tablets types may be produced by compressing two or more layers of granules. Alternatively, multilayer dosage forms may be produced by a process known as “coextrusion”. In essence, the process comprises preparation of at least two different melt compositions as explained above, and passing these molten compositions into a joint coextrusion die. The shape of the coextrusion die depends on the required drug form. For example, dies with a plain die gap, called slot dies, and dies with an annular slit are suitable.
- In order to facilitate the intake of such a dosage form by a mammal, it is advantageous to give the dosage form an appropriate shape. Large tablets that can be swallowed comfortably are therefore preferably elongated rather than round in shape.
- A film coat on the tablet further contributes to the ease with which it can be swallowed. A film coat also improves taste and provides an elegant appearance. If desired, the film-coat may be an enteric coat. The film-coat usually includes a polymeric film-forming material such as hydroxypropyl methylcellulose, hydroxypropylcellulose, and acrylate or methacrylate copolymers. Besides a film-forming polymer, the film-coat may further comprise a plasticizer, e.g. polyethylene glycol, a surfactant, e.g. a Tween® type, and optionally a pigment, e.g. titanium dioxide or iron oxides. The film-coating may also comprise talc as anti-adhesive. The film coat usually accounts for less than about 5% by weight of the dosage form.
- The exact dose and frequency of administration depends on the particular condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art.
- Exemplary compositions of the present invention for combined administration of ritonavir/lopinavir are shown below in Table 1, and the values are % by weight.
TABLE 1 Ritonavir 18-22.5 4.17 4.17 Lopinavir in total 16.67 16.67 Copovidone (N-vinyl 65-75 71.16 70.12 pyrrolidone/vinyl acetate copolymer 60:40) Span 20 (Sorbitan 4-10 7.0 5.02 monolaurate) Cremophor RH40 0-10 — 3.02 (polyoxyethyleneglycerol oxystearate) Colloidal silica 0-3 1.0 1.0 - Exemplary compositions of the invention for administration of ritonavir only are shown below in Table 2. The values are % by weight.
TABLE 2 Ritonavir 18-22.5 20.8 Lopinavir — — Copovidone (N-vinyl 60-75 63.15 pyrrolidone/vinyl acetate copolymer 60:40) Span 20 (Sorbitan 5-15 — monolaurate) in total Cremophor RH40 10.00 (polyoxyethyleneglycerol oxystearate) PEG 6000 0-8 5.00 Colloidal silica 0-3 1.04 - The above compositions are processed by melt extrusion. The resulting extrudates may be used as such or milled and compressed into tablets, preferably by the use of suitable tableting aids such as sodium stearyl fumarate, colloidal silica, lactose, isomalt, calcium silicate, and magnesium stearate, cellulose or calcium hydrogenphosphate.
- The following examples will serve to further illustrate the invention without limiting it.
- Protocol for the oral bioavailability studies
- Dogs (beagle dogs, mixed sexes, weighing approximately 10 kg) received a balanced diet with 27% fat and were permitted water ad libitum. Each dog received a 100 μg/kg subcutaneous dose of histamine approximately 30 minutes prior to dosing. A single dose corresponding to about 200 mg lopinavir, about 50 mg ritonavir, or about 200 mg lopinavir and about 50 mg ritonavir, respectively, was administered to each dog. The dose was followed by approximately 10 milliliters of water. Blood samples were obtained from each animal prior to dosing and 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after drug administration. The plasma was separated from the red cells by centrifugation and frozen (−30° C.) until analysis. Concentrations of HIV protease inhibitors were determined by reverse phase HPLC with low wavelength UV detection following liquid-liquid extraction of the plasma samples. The area under the curve (AUC) was calculated by the trapezoidal method over the time course of the study. Each dosage form was evaluated in a group containing 8 dogs; the values reported are averages for each group of dogs.
- Copovidone (N-vinyl pyrrolidone/vinyl acetate copolymer 60:40; about 78.17 parts by weight) was mixed with ritonavir (about 4.16 parts by weight), lopinavir (about 16.67 parts by weight) and colloidal silica (about 1.0 part by weight). The powdery mixture was then fed into a twin-screw extruder (screw diameter 18 mm) at a rate of about 2.0 kg/h and a melt temperature of about 133° C. The clear, fully transparent melt was fed to a calender with two counter-rotating rollers having mutually matching cavities on their surfaces. Tablets of 1080 mg were thus obtained. DSC and WAXS analysis did not reveal any evidence of crystalline drug material in the formulation.
- The dose-adjusted AUC in dogs was about 0.52 μg.h/ml/100 mg for ritonavir and about 4.54 μg.h/ml/100 mg for lopinavir. This example shows that solid solutions of HIV protease inhibitors without added surfactant yield a very poor bioavailability.
- Copovidone (N-vinyl pyrrolidone/vinyl acetate copolymer 60:40; about 68.17 parts by weight) was blended with Cremophor RH40 (polyoxyethyleneglycerol oxystearate; about 10.00 parts by weight) in a Diosna high-shear mixer. The resulting granules were mixed with ritonavir (about 4.17 parts by weight), lopinavir (about 16.67 parts by weight) and colloidal silica (about 1.00 parts by weight). The powdery mixture was then fed into a Leistritz Micro 18 twin-screw extruder at a rate of about 2.3 kg/h and a melt temperature of about 126° C. The extrudate was cut into pieces and allowed to solidify. The extruded pieces were milled using a high impact universal mill. The milled material (about 86.49 parts by weight) was blended in a bin blender with lactose monohydrate (about 6.00 parts by weight), crosslinked PVP (about 6.00 parts by weight), colloidal silica (about 1.00 part by weight) and magnesium stearate (about 0.51 parts by weight). The powdery blend was compressed to tablets of about 1378.0 mg on a Fette E 1 single punch tablet press. The tablets were then film-coated in a coating pan by spraying an aqueous dispersion for film coating (Opadry, available from Colorcon) at a temperature of about 60° C.
- The dose-adjusted AUC in dogs was about 0.60 μg.h/ml/100 mg for ritonavir and about 7.43 μg.h/ml/100 mg for lopinavir. This example shows that inclusion of a surfactant into solid solutions of HIV protease inhibitors improves the bioavailability attained.
- Copovidone (N-vinyl pyrrolidone/vinyl acetate copolymer 60:40; about 853.8 parts by weight) was blended with Span 20 (Sorbitan monolaurate; about 83.9 parts by weight) in a Diosna high-shear mixer. The resulting granules were mixed with ritonavir (about 50 parts by weight), lopinavir (about 200 parts by weight) and colloidal silica (about 12 parts by weight). The powdery mixture was then fed into a twin-screw extruder (screw diameter 18 mm) at a rate of about 2.1 kg/h and a melt temperature of about 119° C. The extrudate was fed to a calender with two counter-rotating rollers having mutually matching cavities on their surfaces. Tablets of about 1120 mg were thus obtained.
- The dose-adjusted AUC in dogs was about 10.88 μg.h/ml/100 mg for ritonavir and about 51.2 μg.h/ml/100 mg for lopinavir. This example shows that inclusion of a surfactant having an HLB of from about 4 to about 10 into solid solutions of HIV protease inhibitors markedly improves the bioavailability attained.
- Example 2 was repeated, however, the extrudate was cut into pieces and allowed to solidify. The extruded pieces were milled to a particle size of about 250 μm, using a high impact universal mill. The milled material was blended in a bin blender with sodium stearyl fumarate (about 12.3 parts by weight) and colloidal silica (about 8.0 parts by weight) for about 20 min. The powdery blend was compressed on a rotary tablet machine with 3 punches (6500 tablets/h). The tablets were then film-coated in a coating pan by spraying an aqueous dispersion for film coating (Opadry) at a temperature of about 60° C.
- The dose-adjusted AUC in dogs was about 14.24 μg.h/ml/100 mg for ritonavir and about 52.2 μg.h/ml/100 mg for lopinavir.
- Copovidone (N-vinyl pyrrolidonelvinyl acetate copolymer 60:40; about 841.3 parts by weight) was blended with Cremophor RH40 (polyoxyethyleneglycerol oxystearate; about 36.2 parts by weight), Span 20 (Sorbitan monolaurate; about 60.2 parts by weight) in a Diosna high-shear mixer. The resulting granules were mixed with ritonavir (about 50 parts by weight), lopinavir (about 200 parts by weight) and colloidal silica (about 12 parts by weight). The powdery mixture was then fed into a twin-screw extruder (screw diameter 18 mm) at a rate of about 2.1 kg/h and a melt temperature of about 114° C. The extrudate was fed to a calender with two counter-rotating rollers having mutually matching cavities on their surfaces. Tablets of 1120 mg were thus obtained.
- The dose-adjusted AUC in dogs was about 10.96 μg.h/ml/100 mg for ritonavir and about 46.5 μg.h/ml/100 mg for lopinavir. This example shows that a combination of a surfactant having an HLB of from about 4 to about 10 and a further surfactant can successfully be used.
- Example 4 was repeated, however, the extrudate was cut into pieces and allowed to solidify. The extruded pieces were milled to a particle size of about 250 μm, using a high impact universal mill. The milled material was blended in a bin blender with sodium stearylfumarate (about 13.9 parts by weight), colloidal silica (about 7.0 parts by weight), isomalt DC100 (about 159.4 parts by weight) and calcium silicate (about 7.0 parts by weight) for about 20 min. The blend was compressed and film-coated as described in example 1.
- The dose-adjusted AUC in dogs was about 10.38 μg.h/ml/100 mg for ritonavir and about 42.7 μg.h/ml/100 mg for lopinavir.
- Copovidone (N-vinyl pyrrolidone/vinyl acetate copolymer 60:40; about 683.3 parts by weight) was blended with Span 40 (sorbitan monopalmitate; about 67.2 parts by weight) in a Diosna high-shear mixer. The resulting granules were mixed with lopinavir (about 200 parts by weight) and colloidal silica (about 9.6 parts by weight). The powdery mixture was then fed into a twin-screw extruder (screw diameter 18 mm) at a rate of about 2.1 kg/h and a melt temperature of about 119° C. The extrudate was cut into pieces and allowed to solidify. The extruded pieces were milled using a high impact universal mill. The milled material was blended in a bin blender with sodium stearylfumarate (about 7.9 parts by weight), colloidal silica (about 11.3 parts by weight), isomalt DC100 (about 129.1 parts by weight) and sodium dodecyl sulfate (about 15.6 parts by weight). The blend was compressed and film-coated as described in example 1.
- Tablets corresponding to about 200 mg lopinavir were coadministered to dogs together with about 50 mg ritonavir. The dose-adjusted AUC of lopinavir was about 38.8 μg.h/ml/100 mg.
- Copovidone (N-vinyl pyrrolidone/vinyl acetate copolymer 60:40; about 151.5 parts by weight) was blended with Cremophor RH40 (about 24 parts by weight) and PEG 6000 (about 12 parts by weight) in a Diosna high-shear mixer. The resulting granules were mixed with ritonavir (about 50 parts by weight) and colloidal silica (about 2.4 parts by weight). The powdery mixture was then fed into a twin-screw extruder and was melt-extruded. The extrudate was cut into pieces and allowed to solidify. The extruded pieces were milled using a high impact universal mill. The milled material was blended in a bin blender with colloidal silica (about 1.4 parts by weight), isomalt DC100 (about 31.9 parts by weight) and calcium silicate (about 4.2 parts by weight). The blend was compressed and film-coated as described in example 1.
- The dose-adjusted AUC in dogs was about 9.98 μg.h/ml/100 mg.
Claims (40)
1. A solid pharmaceutical dosage form which comprises a solid dispersion of at least one HIV protease inhibitor in at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, wherein said HIV protease inhibitor is selected from the group consisting of (2S,3S,5S)-5-(N-(N-(N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane (lopinavir), and said water-soluble polymer has a Tg of at least about 50° C. and is present in an amount of from about 50 to about 85% by weight of the dosage form.
2. The dosage form of claim 1 , wherein said solid dispersion is a glassy solution or solid solution, and consists of one phase.
3. The dosage form of claim 2 , wherein said surfactant has an HLB value of from about 4 to about 10.
4. The dosage form of claim 2 , wherein said solid dispersion further comprises another pharmaceutically acceptable surfactant.
5. The dosage form of claim 2 , wherein said surfactant is a sorbitan fatty acid ester.
6. The dosage form of claim 2 which comprises, relative to the weight of the dosage form, from about 5 to about 30% by weight of said HIV protease inhibitor, from about 2 to about 20% by weight of said surfactant, and from about 0 to about 15% by weight of additives.
7. The dosage form of claim 2 , wherein said HIV protease inhibitor is ritonavir.
8. The dosage form of claim 7 which has a dose-adjusted AUC, in dogs under non-fasting conditions, of ritonavir plasma concentration of at least about 9 μg h/ml/100 mg.
9. The dosage form of claim 2 , wherein said HIV protease inhibitor is lopinavir.
10. The dosage form of claim 9 which has a dose-adjusted AUC, in dogs under non-fasting conditions, of lopinavir plasma concentration of at least about 20 μg h/ml/100 mg.
11. The dosage form of claim 2 , wherein said at least one HIV protease inhibitor includes ritonavir and lopinavir.
12. The dosage form of claim 11 which has a dose-adjusted AUC, in dogs under non-fasting conditions, of ritonavir plasma concentration of at least about 9 μg h/ml/100 mg and a dose-adjusted AUC of lopinavir plasma concentration of at least about 20 μg h/ml/100 mg.
13. The dosage form of claim 2 , wherein said water-soluble polymer has a Tg of from about 80 to about 180° C.
14. The dosage form of claim 2 , wherein said water-soluble polymer is a homopolymer or copolymer of N-vinyl pyrrolidone.
15. The dosage form of claim 2 , wherein said water-soluble polymer is a copolymer of N-vinyl pyrrolidone and vinyl acetate.
16. The dosage form of claim 2 comprising at least one additive selected from flow regulators, disintegrants, bulking agents or lubricants.
17. The dosage form of claim 2 which contains, upon storage for about 6 weeks at about 40° C. and about 75% humidity, at least about 98% of the initial content of HIV protease inhibitor.
18. The dosage form of claim 1 , wherein said water-soluble polymer has a Tg of from about 80 to about 180° C., and said surfactant has an HLB value of from about 4 to about 10 and is present in an amount of from about 2 to about 20% by weight of the dosage form.
19. The dosage form of claim 1 , wherein said water-soluble polymer is a copolymer of N-vinyl pyrrolidone and vinyl acetate, and said surfactant is a sorbitan fatty acid ester which has an HLB value of from about 4 to about 10 and is present in an amount of from about 2 to about 20% by weight of the dosage form.
20. A process of preparing a solid dosage form of claim 1 , comprising:
preparing a melt comprising said at last one HIV protease inhibitor, said at least one pharmaceutically acceptable water-soluble polymer and said at least one pharmaceutically acceptable surfactant; and
allowing the melt to solidify to obtain said solid dispersion.
21. The process of claim 20 , comprising grinding and compressing said solid dispersion into a tablet.
22. A solid pharmaceutical dosage form comprising a solid dispersion of ritonavir in at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, wherein said water-soluble polymer has a Tg of at least about 50° C. and is present in an amount of from about 50% to about 85% by weight of the dosage form.
23. The dosage form of claim 22 , wherein said water-soluble polymer has a Tg of from about 80 to about 180° C.
24. The dosage form of claim 22 , wherein said water-soluble polymer is a copolymer of N-vinyl pyrrolidone and vinyl acetate.
25. The dosage form of claim 22 , wherein said water-soluble polymer is a homopolymer or copolymer of N-vinyl pyrrolidone.
26. A solid pharmaceutical dosage form comprising a solid dispersion of ritonavir and lopinavir in at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, wherein said water-soluble polymer has a Tg of at least about 50° C. and is present in an amount of from about 50 to about 85% by weight of the dosage form, and said surfactant has an HLB value of from about 4 to about 10 and is present in an amount of from about 2 to about 20% by weight of the dosage form.
27. The dosage form of claim 26 , wherein said solid dispersion is a glassy or solid solution, and consists of one phase.
28. The dosage form of claim 26 , wherein said water-soluble polymer has a Tg of from about 80 to about 180° C.
29. The dosage form of claim 26 , wherein said water-soluble polymer is a copolymer of N-vinyl pyrrolidone and vinyl acetate, and said surfactant is a sorbitan fatty acid ester.
30. The dosage form of claim 26 , wherein said water-soluble polymer is a homopolymer or copolymer of N-vinyl pyrrolidone, and said surfactant is a sorbitan fatty acid ester.
31. The dosage form of claim 26 , wherein said water-soluble polymer is copovidone, and said surfactant is sorbitan monolaurate.
32. The dosage form of claim 26 comprising at least one additive selected from flow regulators, disintegrants, bulking agents or lubricants.
33. A solid pharmaceutical dosage form comprising a solid or glassy solution of ritonavir and lopinavir in a matrix comprising a sorbitan fatty acid ester and a copolymer of N-vinyl pyrrolidone and vinyl acetate, wherein said ritonavir and lopinavir are present in an amount of from about 5 to about 30% by weight of the dosage form, said co-polymer is present in an amount of from about 50% to about 85% by weight of the dosage form, and said sorbitan fatty acid ester is present in an amount of from about 2% to about 20% by weight of the dosage form.
34. The dosage form of claim 33 , wherein said copolymer is copovidone, and said sorbitan fatty acid ester is sorbitan monolaurate.
35. A solid pharmaceutical dosage form comprising a one-phase solid or glassy solution of at least one HIV protease inhibitor in at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, wherein said water-soluble polymer has a Tg of at least about 50° C. and is present in an amount of from about 50 to about 85% by weight of the dosage form.
36. The dosage form of claim 35 , wherein said surfactant has an HLB value of from about 4 to about 10.
37. A method of treating HIV infection, comprising administering the solid dosage form of claim 1 to a mammal in need of such treatment.
38. A solid pharmaceutical dosage form which comprises a solid dispersion of at least one HIV protease inhibitor in at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, wherein said water-soluble polymer has a Tg of at least about 50° C. and is present in an amount of from about 50 to about 85% by weight of the dosage form.
39. A process of preparing a solid dosage form of claim 38 , comprising:
preparing a melt comprising said at last one HIV protease inhibitor, said at least one pharmaceutically acceptable water-soluble polymer and said at least one pharmaceutically acceptable surfactant; and
allowing the melt to solidify to obtain said solid dispersion.
40. A method of treating HIV infection, comprising administering the solid dosage form of claim 38 to a mammal in need of such treatment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/773,185 US20070249643A1 (en) | 2003-08-28 | 2007-07-03 | Solid pharmaceutical dosage form |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49841203P | 2003-08-28 | 2003-08-28 | |
US10/925,442 US8025899B2 (en) | 2003-08-28 | 2004-08-25 | Solid pharmaceutical dosage form |
US11/773,185 US20070249643A1 (en) | 2003-08-28 | 2007-07-03 | Solid pharmaceutical dosage form |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/925,442 Continuation US8025899B2 (en) | 2003-08-28 | 2004-08-25 | Solid pharmaceutical dosage form |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070249643A1 true US20070249643A1 (en) | 2007-10-25 |
Family
ID=34526332
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/925,442 Expired - Fee Related US8025899B2 (en) | 2003-08-28 | 2004-08-25 | Solid pharmaceutical dosage form |
US11/773,185 Abandoned US20070249643A1 (en) | 2003-08-28 | 2007-07-03 | Solid pharmaceutical dosage form |
US12/880,766 Expired - Fee Related US8333990B2 (en) | 2003-08-28 | 2010-09-13 | Solid pharmaceutical dosage form |
US12/880,781 Expired - Fee Related US8309613B2 (en) | 2003-08-28 | 2010-09-13 | Solid pharmaceutical dosage form |
US13/240,119 Expired - Fee Related US8399015B2 (en) | 2003-08-28 | 2011-09-22 | Solid pharmaceutical dosage form |
US13/449,958 Active US8268349B2 (en) | 2003-08-28 | 2012-04-18 | Solid pharmaceutical dosage form |
US13/674,799 Expired - Fee Related US8691878B2 (en) | 2003-08-28 | 2012-11-12 | Solid pharmaceutical dosage form |
US14/190,618 Abandoned US20140179721A1 (en) | 2003-08-28 | 2014-02-26 | Solid pharmaceutical dosage form |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/925,442 Expired - Fee Related US8025899B2 (en) | 2003-08-28 | 2004-08-25 | Solid pharmaceutical dosage form |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/880,766 Expired - Fee Related US8333990B2 (en) | 2003-08-28 | 2010-09-13 | Solid pharmaceutical dosage form |
US12/880,781 Expired - Fee Related US8309613B2 (en) | 2003-08-28 | 2010-09-13 | Solid pharmaceutical dosage form |
US13/240,119 Expired - Fee Related US8399015B2 (en) | 2003-08-28 | 2011-09-22 | Solid pharmaceutical dosage form |
US13/449,958 Active US8268349B2 (en) | 2003-08-28 | 2012-04-18 | Solid pharmaceutical dosage form |
US13/674,799 Expired - Fee Related US8691878B2 (en) | 2003-08-28 | 2012-11-12 | Solid pharmaceutical dosage form |
US14/190,618 Abandoned US20140179721A1 (en) | 2003-08-28 | 2014-02-26 | Solid pharmaceutical dosage form |
Country Status (1)
Country | Link |
---|---|
US (8) | US8025899B2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009108865A2 (en) * | 2008-02-28 | 2009-09-03 | Abbott Laboratories | Tablets and preparation thereof |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
EP2819668A4 (en) * | 2012-03-01 | 2015-07-29 | Hetero Research Foundation | Ritonavir compositions |
US9107830B2 (en) | 1999-11-12 | 2015-08-18 | Abbvie, Inc. | Inhibitors of crystallization in a solid dispersion |
WO2019219823A1 (en) * | 2018-05-18 | 2019-11-21 | Pharmaceutical Oriented Services Ltd. | Solid dispersion containing ritonavir |
RU2711359C2 (en) * | 2009-06-08 | 2020-01-16 | Эббви Дойчланд Гмбх Унд Ко. Кг | Pharmaceutical dosage form for oral administration of bcl-2 family inhibitor |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1694657A1 (en) * | 2003-12-09 | 2006-08-30 | Pfizer Inc. | Compositions comprising an hiv protease inhibitor |
EP1912625B1 (en) | 2005-08-08 | 2016-04-13 | AbbVie Deutschland GmbH & Co KG | Itraconazole compositions with improved bioavailability |
PT1912626T (en) * | 2005-08-08 | 2016-07-20 | Abbvie Deutschland | Dosage forms with improved bioavailability |
WO2007087188A2 (en) * | 2006-01-20 | 2007-08-02 | Merck & Co., Inc. | Taste-masked tablets and granules |
AU2007283196A1 (en) * | 2006-08-10 | 2008-02-14 | Cipla Limited | Antiretroviral solid oral composition |
WO2008067164A2 (en) * | 2006-11-15 | 2008-06-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
AU2008218186C1 (en) | 2007-02-23 | 2014-07-17 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
EP2207892A4 (en) * | 2007-10-15 | 2010-12-08 | Precision Therapeutics Inc | Methods for selecting active agents for cancer treatment |
PA8809601A1 (en) * | 2007-12-24 | 2009-07-23 | Cipla Ltd | ANTI-RETROVIRAL COMBINATION |
AU2009242451C1 (en) | 2008-05-02 | 2017-05-18 | Gilead Sciences, Inc. | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
BRPI0920604B1 (en) † | 2008-10-07 | 2021-11-23 | Kudos Pharmaceuticals Limited | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION IN THE FORM OF A SOLID DISPERSION COMPRISING AS ACTIVE THE COMPOUND 4-[3-(4-CYCLOPROPANCARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORINE-BENZYL]-2H-PHTALAZIN-1-ONE (OLAPARIB) |
EP2391350A1 (en) * | 2008-12-18 | 2011-12-07 | Ranbaxy Laboratories Limited | Atazanavir formulations |
NZ591973A (en) | 2009-06-11 | 2013-03-28 | Abbott Lab | Anti-viral compounds to treat hcv infection |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US20110034489A1 (en) * | 2009-07-31 | 2011-02-10 | Ranbaxy Laboratories Limited | Solid dosage forms of hiv protease inhibitors |
CN103118681B (en) * | 2010-03-10 | 2015-02-18 | 艾伯维巴哈马有限公司 | Solid compositions |
NZ605440A (en) * | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
UA113500C2 (en) | 2010-10-29 | 2017-02-10 | MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | |
US9174944B1 (en) | 2010-12-17 | 2015-11-03 | Abbvie Inc. | Crystalline lopinavir/surfactant adducts |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US9096556B2 (en) | 2011-05-27 | 2015-08-04 | Hetero Research Foundation | Amorphous ritonavir co-precipitated |
KR101794032B1 (en) | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | Method for preparing nanoparticles |
US20140288108A1 (en) | 2011-11-28 | 2014-09-25 | Ranbaxy Laboratories Limited | Process for the preparation of solid dispersion of lopinavir and ritonavir |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
EP2649989B1 (en) | 2012-04-13 | 2017-10-18 | King Saud University | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof |
US20140024613A1 (en) | 2012-06-27 | 2014-01-23 | Abbvie Inc. | Methods for Treating HCV |
CN103655571B (en) * | 2012-09-11 | 2016-04-20 | 上海星泰医药科技有限公司 | A kind of Lopinavir and ritonavir compound recipe high evenness nanometer are divided into prose style free from parallelism and preparation method thereof |
RU2505286C1 (en) | 2012-12-29 | 2014-01-27 | Открытое Акционерное Общество "Фармасинтез" | Pharmaceutical composition for treating hiv infection, method for preparing it, and method of treating |
WO2014130553A2 (en) * | 2013-02-20 | 2014-08-28 | Abbvie Inc. | Tablet dosage forms |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
CA2918707A1 (en) | 2013-08-29 | 2015-03-05 | Teva Pharmaceuticals Industries Ltd. | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
TW201622731A (en) | 2014-04-08 | 2016-07-01 | 泰瓦藥品工業有限公司 | Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising darunavir and ritonavir |
WO2016134058A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
US10034865B2 (en) | 2015-09-10 | 2018-07-31 | Kashiv Pharma, Llc | Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof |
RU2659693C1 (en) * | 2017-06-30 | 2018-07-03 | Общество с ограниченной ответственностью "Изварино Фарма" | Pharmaceutical composition having anti-hiv infection activity |
CN110354081A (en) * | 2019-08-01 | 2019-10-22 | 聊城高新生物技术有限公司 | The preparation method for the Ritonavir solid dispersions being precipitated in an aqueous medium can be reduced |
CN114557967B (en) * | 2022-03-17 | 2023-06-02 | 乐普制药科技有限公司 | Preparation method of ritonavir solid dispersion |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6579521B2 (en) * | 2000-10-20 | 2003-06-17 | Chiron Corporation | Methods of therapy for HIV infection |
US6599528B1 (en) * | 1999-03-25 | 2003-07-29 | Abbott Gmbh & Co. Kg | Mechanically stable pharmaceutical presentations form containing liquid or semisolid surface-active substances |
Family Cites Families (430)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US619777A (en) * | 1899-02-21 | Type-writing machine | ||
DE973095C (en) | 1955-01-19 | 1959-12-03 | Kalle & Co Ag | Process for converting oils into powders that can be sprinkled by spray-drying oil-in-water emulsions |
HU176101B (en) | 1977-12-29 | 1980-12-28 | Gyogyszerkutato Intezet | Process for producing bis-bracket-nitrozo-ureido-bracket closed-polyol derivatives |
DE3013839A1 (en) | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | METHOD FOR PRODUCING AN ACTIVATED PHARMACEUTICAL COMPOSITION |
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
FR2525108B1 (en) | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | HIGH-SOLUBILITY MEDICINES AND PROCESS FOR OBTAINING THEM |
US4620974A (en) | 1983-07-07 | 1986-11-04 | American Home Products Corporation | Pharmaceutical composition containing a liquid lubricant |
US4769235A (en) | 1984-01-27 | 1988-09-06 | New York University | Immunodominant epitope of the circumsporozoite surface protein |
US4629621A (en) | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
JPS61205208A (en) | 1985-03-08 | 1986-09-11 | Yamanouchi Pharmaceut Co Ltd | Rapidly solubilizing preparation for hard-soluble medicines |
US4590065A (en) | 1985-04-18 | 1986-05-20 | Colgate-Palmolive Company | Stable flavor-containing dentifrice |
US4758427A (en) | 1985-08-08 | 1988-07-19 | Ciba-Geigy Corporation | Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone |
PH22025A (en) | 1985-08-19 | 1988-05-13 | Johnson & Son Inc S C | Aqueous pyrethroid insecticidal formulations and method of increasing the stability thereof |
DE3612212A1 (en) | 1986-04-11 | 1987-10-15 | Basf Ag | METHOD FOR PRODUCING SOLID PHARMACEUTICAL FORMS |
DE3612211A1 (en) | 1986-04-11 | 1987-10-15 | Basf Ag | CONTINUOUS TABLET METHOD |
IT1221893B (en) | 1986-05-30 | 1990-07-12 | Giuseppe Gagliani | CONTINUOUS INDUSTRIAL MIXING PROCEDURE THROUGH SPECIAL CONFORMATION OF THE EXTRUDER SCREW |
DE3682208D1 (en) | 1986-12-18 | 1991-11-28 | Kurt Heinz Bauer | STABILIZED NIFEDIPINE CONCENTRATE AGAINST THE INFLUENCE OF LIGHT AND METHOD FOR THE PRODUCTION THEREOF. |
US4804699A (en) | 1987-05-15 | 1989-02-14 | Ici Americas Inc. | Monomeric and oligomeric glutarate-based light stabilizers for plastics |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
AU2902289A (en) | 1987-12-08 | 1989-07-05 | Mark Chasin | Method of forming bioerodible implants for improved controlled drug release |
DE3812567A1 (en) | 1988-04-15 | 1989-10-26 | Basf Ag | METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES |
DE3830353A1 (en) | 1988-09-07 | 1990-03-15 | Basf Ag | METHOD FOR THE CONTINUOUS PRODUCTION OF SOLID PHARMACEUTICAL FORMS |
US5368864A (en) | 1988-11-25 | 1994-11-29 | Henning Berlin Gmbh Chemie- Und Pharmawerk | Formulation of oxypurinol and/or its alkali and alkaline earth salts |
DE3839825A1 (en) | 1988-11-25 | 1990-06-13 | Henning Berlin Gmbh | SOLIDS DISPERSIONS CONTAIN OXIPURINOL AND / OR ITS ALKALI OR EARTH ALKALISALZE |
US5028433A (en) | 1988-11-30 | 1991-07-02 | Banyu Pharmaceutical Co., Ltd. | Readily absorbable drug formulation of NB-818 |
GB8903328D0 (en) | 1989-02-14 | 1989-04-05 | Ethical Pharma Ltd | Nifedipine-containing pharmaceutical compositions and process for the preparation thereof |
US5696270A (en) | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
HU204529B (en) | 1989-08-10 | 1992-01-28 | Richter Gedeon Vegyeszet | Process for producing new 1-oxa-2-oxo-8-aza-spiro(4,5)decane derivatives and pharmaceutical compositions containing them |
EP0421582A1 (en) | 1989-10-03 | 1991-04-10 | Warner-Lambert Company | Chewable spray dried spheroidal microcapsules and polymer coated microcapsules and method for preparing same |
EP0421581A1 (en) | 1989-10-03 | 1991-04-10 | Warner-Lambert Company | Chewable spray dried spheroidal microcapsules and wax coated microcapsules and methods for preparing same |
US5075291A (en) | 1989-11-22 | 1991-12-24 | Ici Americas Inc. | Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound |
AU648573B2 (en) | 1990-06-01 | 1994-04-28 | Research Corporation Technologies, Inc. | Self-emulsifying glasses |
SE9003296L (en) | 1990-10-16 | 1992-04-17 | Kabi Pharmacia Ab | PROCEDURE SHOULD FORMULATE MEDICINAL PRODUCTS |
ATE157368T1 (en) | 1990-11-28 | 1997-09-15 | Taisho Pharmaceutical Co Ltd | 6-0-METHYLERYTHROMYCIN A DERIVATIVE |
ATE159426T1 (en) | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING A SOLID DISPERSION |
WO1993007859A1 (en) | 1991-10-23 | 1993-04-29 | Warner-Lambert Company | Novel pharmaceutical pellets and process for their production |
DE4138513A1 (en) | 1991-11-23 | 1993-05-27 | Basf Ag | SOLID PHARMACEUTICAL RETARD FORM |
DE69222182T2 (en) | 1991-12-18 | 1998-02-26 | Warner Lambert Co | METHOD FOR PRODUCING A SOLID DISPERSION |
DE4200821A1 (en) | 1992-01-15 | 1993-07-22 | Bayer Ag | TASTE-MASKED PHARMACEUTICAL AGENTS |
DE4201179A1 (en) | 1992-01-17 | 1993-07-22 | Alfatec Pharma Gmbh | Granulates or pellets comprising dispersion of active agent in hydrophilic macromolecules - are e.g. for treatment of depression, hypertension, rheumatism, etc. |
ATE217526T1 (en) | 1992-02-18 | 2002-06-15 | Pharmos Corp | DRY COMPOSITIONS FOR PRODUCING EMULSIONS IN THE SUBMICRON RANGE |
US5654003A (en) | 1992-03-05 | 1997-08-05 | Fuisz Technologies Ltd. | Process and apparatus for making tablets and tablets made therefrom |
MX9301817A (en) | 1992-03-30 | 1994-01-31 | Alza Corp | POLYMERIC SYSTEM CONTAINING A PARTIALLY SOLUBLE COMPOUND. |
CA2095776C (en) | 1992-05-12 | 2007-07-10 | Richard C. Fuisz | Rapidly dispersable compositions containing polydextrose |
US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
IT1256026B (en) | 1992-06-12 | 1995-11-20 | SALTS OF ETHYL ESTER GLUTATION | |
DE4220782A1 (en) | 1992-06-25 | 1994-01-05 | Basf Ag | Process for the preparation of solid pharmaceutical sustained release forms |
DE4226753A1 (en) | 1992-08-13 | 1994-02-17 | Basf Ag | Preparations containing active substances in the form of solid particles |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
IS2334B (en) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl protease inhibitor of a new class of sulfonamides |
WO1994008568A1 (en) | 1992-10-16 | 1994-04-28 | Nippon Shinyaku Co., Ltd. | Method of manufacturing wax matrices |
US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
GB9306887D0 (en) | 1993-04-01 | 1993-05-26 | Graham Neil B | Random block copolymers |
DE69428707T2 (en) | 1993-08-20 | 2002-07-11 | Nippon Shinyaku Co Ltd | PREPARATION IN THE STOMACH, SOURCING MOLDED BODY AND PRODUCTION PROCESS |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
WO1995014037A1 (en) | 1993-11-17 | 1995-05-26 | Ibah, Inc. | Transparent liquid for encapsulated drug delivery |
KR100354702B1 (en) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | Manufacturing method and sustained release composition of pharmaceutical composition |
IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
DK0744941T3 (en) | 1994-02-16 | 2003-09-29 | Abbott Lab | Process for preparing finely divided pharmaceutical formulations |
WO1995022962A1 (en) | 1994-02-23 | 1995-08-31 | Bm Research A/S | Controlled release composition |
DE4413350A1 (en) | 1994-04-18 | 1995-10-19 | Basf Ag | Retard matrix pellets and process for their production |
IL129871A (en) | 1994-05-06 | 2003-11-23 | Pharmacia & Upjohn Inc | Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections |
DE19509807A1 (en) | 1995-03-21 | 1996-09-26 | Basf Ag | Process for the preparation of active substance preparations in the form of a solid solution of the active substance in a polymer matrix, and active substance preparations produced using this method |
US5443178A (en) | 1994-06-23 | 1995-08-22 | Allergan, Inc. | Tablet dispensing system |
FR2722984B1 (en) | 1994-07-26 | 1996-10-18 | Effik Lab | PROCESS FOR THE PREPARATION OF DRY PHARMACEUTICAL FORMS AND THE PHARMACEUTICAL COMPOSITIONS THUS PRODUCED |
WO1996010397A1 (en) | 1994-09-30 | 1996-04-11 | Takeda Chemical Industries, Ltd. | Oral sustained-release preparation |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
DE4446468A1 (en) | 1994-12-23 | 1996-06-27 | Basf Ag | Process for the production of coated tablets |
DE4446467A1 (en) | 1994-12-23 | 1996-06-27 | Basf Ag | Process for the production of lenticular tablets by melt calendering |
DE4446470A1 (en) | 1994-12-23 | 1996-06-27 | Basf Ag | Process for the production of dividable tablets |
US5545628A (en) | 1995-01-10 | 1996-08-13 | Galephar P.R. Inc. | Pharmaceutical composition containing fenofibrate |
DE19500977C2 (en) | 1995-01-14 | 1999-01-07 | Lohmann Therapie Syst Lts | Solid drug form with active ingredient distributed in polymeric material |
NZ270439A (en) | 1995-02-02 | 1996-04-26 | Bernard Charles Sherman | Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer |
DE19504832A1 (en) | 1995-02-14 | 1996-08-22 | Basf Ag | Solid drug preparations |
DE19509806A1 (en) | 1995-03-21 | 1996-09-26 | Basf Ag | Storage stable dosage forms |
DE19509805A1 (en) | 1995-03-21 | 1996-09-26 | Basf Ag | Transparent, fast-release formulations of nonsteroidal analgesics |
ATE287703T1 (en) | 1995-04-14 | 2005-02-15 | Nektar Therapeutics | POWDERED PHARMACEUTICAL FORMULATIONS WITH IMPROVED DISPERSIBILITY |
SI9500173B (en) | 1995-05-19 | 2002-02-28 | Lek, | Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application |
US5567823A (en) | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
SE9502244D0 (en) | 1995-06-20 | 1995-06-20 | Bioglan Ab | A composition and a process for the preparation thereof |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
FR2736550B1 (en) | 1995-07-14 | 1998-07-24 | Sandoz Sa | PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID DISPERSION COMPRISING A MACROLIDE AND A VEHICLE |
TW487582B (en) | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
US6221399B1 (en) | 1995-08-17 | 2001-04-24 | Csir | Method of making controlled release particles of complexed polymers |
DE19531277A1 (en) | 1995-08-25 | 1997-02-27 | Basf Ag | Use of lipids as an aid in the production of solid dosage forms by the melt extrusion process |
US6391338B1 (en) | 1995-09-07 | 2002-05-21 | Biovail Technologies Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
DE19536394A1 (en) | 1995-09-29 | 1997-04-03 | Basf Ag | Solid pharmaceutical forms, obtainable by extrusion of a polymer-active substance melt containing isomalt |
DE19536387A1 (en) | 1995-09-29 | 1997-04-03 | Basf Ag | Process for the preparation of vitamin-containing solid preparations |
EP0862420A4 (en) | 1995-10-13 | 1999-11-03 | Penn State Res Found | Synthesis of drug nanoparticles by spray drying |
DE19539361A1 (en) | 1995-10-23 | 1997-04-24 | Basf Ag | Process for the preparation of multilayer, solid pharmaceutical forms for oral or rectal administration |
DE19539574A1 (en) | 1995-10-25 | 1997-04-30 | Boehringer Mannheim Gmbh | Preparations and processes for stabilizing biological materials by means of drying processes without freezing |
US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
DE19602206A1 (en) | 1996-01-23 | 1997-07-24 | Basf Ag | Preparations of nonsteroidal analgesics |
US5762961A (en) | 1996-02-09 | 1998-06-09 | Quadrant Holdings Cambridge Ltd. | Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof |
US5958455A (en) | 1996-02-09 | 1999-09-28 | Quadrant Holdings Cambridge Ltd | Oral solid dosage forms, methods of making same and compositions thereof |
GB2311027B (en) | 1996-03-15 | 1999-10-27 | Johnson & Johnson Medical | Coated bioabsorbable beads for wound treatment |
US20030064108A1 (en) | 1996-04-23 | 2003-04-03 | Stefan Lukas | Taste masked pharmaceutical compositions |
DE19617716A1 (en) | 1996-05-03 | 1997-11-06 | Basf Ag | Polymer powder redispersible in aqueous solution |
WO1997044014A1 (en) | 1996-05-20 | 1997-11-27 | Janssen Pharmaceutica N.V. | Antifungal compositions with improved bioavailability |
US5834472A (en) | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
KR100307427B1 (en) | 1996-05-24 | 2001-12-28 | 둘락 노먼 씨. | Antifungal composition with improved bioavailability |
US6764690B2 (en) | 1996-05-29 | 2004-07-20 | Delsitech Oy | Dissolvable oxides for biological applications |
WO1997046222A1 (en) | 1996-06-03 | 1997-12-11 | Merck & Co., Inc. | Pediatric formulation for hiv protease inhibitors |
US5935936A (en) | 1996-06-03 | 1999-08-10 | Genzyme Corporation | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules |
DE19624607A1 (en) | 1996-06-20 | 1998-01-02 | Basf Ag | Process for the preparation of salts of pharmaceutical active substances bearing acid groups |
DK1014941T3 (en) | 1996-06-26 | 2009-07-27 | Univ Texas | Extrudable pharmaceutical hot-melt formulation |
DE19629753A1 (en) | 1996-07-23 | 1998-01-29 | Basf Ag | Process for the production of solid dosage forms |
DE19635676A1 (en) | 1996-09-03 | 1998-03-05 | Basf Ag | Solid foamed active ingredient preparations |
HRP970485A2 (en) | 1996-09-13 | 1998-08-31 | Joerg Rosenberg | Process for producing solid pharmaceutical forms |
DE19637479A1 (en) | 1996-09-13 | 1998-03-19 | Basf Ag | Preparation of solid pharmaceutical forms |
US6071539A (en) | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
US6649186B1 (en) | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
US6488961B1 (en) | 1996-09-20 | 2002-12-03 | Ethypharm, Inc. | Effervescent granules and methods for their preparation |
US5727878A (en) * | 1996-10-17 | 1998-03-17 | Cdf Corporation | Liner for a mixing container and an assembly and method for mixing fluid components |
US8828432B2 (en) | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
US20010006677A1 (en) | 1996-10-29 | 2001-07-05 | Mcginity James W. | Effervescence polymeric film drug delivery system |
ID24271A (en) | 1996-11-15 | 2000-07-13 | Merck Patent Gmbh | PROCESS FOR PRODUCING POLYOL MATERIALS WHICH IS FORMED OR NOT FORMED |
ZA9710071B (en) | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
US6232333B1 (en) | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
FR2756736B1 (en) | 1996-12-05 | 1999-03-05 | Sanofi Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING N-SULFONYL INDOLINE DERIVATIVES |
TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
US6197787B1 (en) | 1997-03-03 | 2001-03-06 | Sanofi-Synthelabo | Pharmaceutical formulations containing poorly soluble drug substances |
DE19709663A1 (en) | 1997-03-10 | 1998-09-17 | Basf Ag | Use of redispersible polymer powders or polymer granules as binders for the production of solid pharmaceutical dosage forms |
DE19710213A1 (en) | 1997-03-12 | 1998-09-17 | Basf Ag | Process for the manufacture of solid combination dosage forms |
DE19710009A1 (en) | 1997-03-12 | 1998-09-24 | Knoll Ag | Multi-phase preparation forms containing active ingredients |
US5948426A (en) | 1997-05-03 | 1999-09-07 | Jefferies; Steven R. | Method and article to induce hematopoietic expansion |
US6610764B1 (en) | 1997-05-12 | 2003-08-26 | Metabolix, Inc. | Polyhydroxyalkanoate compositions having controlled degradation rates |
DE19721467A1 (en) | 1997-05-22 | 1998-11-26 | Basf Ag | Process for the preparation of small-scale preparations of biologically active substances |
GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
US5955475A (en) | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
JPH1125076A (en) | 1997-06-30 | 1999-01-29 | Fujitsu Ltd | Document managing device and document management program storage medium |
US5889051A (en) | 1997-07-15 | 1999-03-30 | Development Center For Biotechnology | Stabilization of prostaglandin drug |
DE19733505A1 (en) | 1997-08-01 | 1999-02-04 | Knoll Ag | Fast acting analgesic |
PT901786E (en) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Solid pharmaceutical dispersions with enhanced bioavailability |
HN1998000115A (en) | 1997-08-21 | 1999-06-02 | Warner Lambert Co | SOLID PHARMACEUTICAL DOSAGE FORMS |
US6692767B2 (en) | 1997-09-19 | 2004-02-17 | Shire Laboratories Inc. | Solid solution beadlet |
JP3460538B2 (en) | 1997-10-08 | 2003-10-27 | 救急薬品工業株式会社 | Fast dissolving film preparation |
US20020164374A1 (en) | 1997-10-29 | 2002-11-07 | John Jackson | Polymeric systems for drug delivery and uses thereof |
US6027747A (en) | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
DE59803468D1 (en) | 1997-11-28 | 2002-04-25 | Knoll Ag | METHOD FOR PRODUCING SOLVENT-FREE, NON-CRYSTALLINE BIOLOGICALLY ACTIVE SUBSTANCES |
DE19753298A1 (en) | 1997-12-01 | 1999-06-02 | Basf Ag | Process for the preparation of solid dosage forms |
US6632455B2 (en) | 1997-12-22 | 2003-10-14 | Schering Corporation | Molecular dispersion composition with enhanced bioavailability |
JPH11271927A (en) * | 1998-01-20 | 1999-10-08 | Mitsubishi Paper Mills Ltd | Supporting body for image material |
GB9802088D0 (en) | 1998-01-30 | 1998-03-25 | Scherer Ltd R P | Pharmaceutical products |
US6787157B1 (en) | 1998-03-10 | 2004-09-07 | Abbott Laboratories | Multiphase active ingredient-containing formulations |
NZ506903A (en) | 1998-03-16 | 2003-01-31 | Yamanouchi Pharma Tech Inc | Tablets quickly disintegrating in the oral cavity and process for producing the same |
DE19812688A1 (en) | 1998-03-23 | 1999-09-30 | Basf Ag | Solid dosage forms useful for slow release of drugs, fragrances, plant-treating agents, animal feed additives and food additives |
DE19814739A1 (en) | 1998-04-02 | 1999-10-07 | Basf Ag | Solubilizing agents useful in pharmaceutical, cosmetic and food compositions |
US20040062802A1 (en) | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
US5945123A (en) | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
DE19814730A1 (en) | 1998-04-02 | 1999-10-07 | Basf Ag | Pharmaceutical and cosmetic compositions with matrix containing N-vinyllactam or N-vinylamine based copolymer |
AU763143B2 (en) | 1998-04-08 | 2003-07-17 | Kyowa Hakko Kirin Co., Ltd. | Tablet manufacturing method and tablet |
EP1073693A1 (en) | 1998-04-24 | 2001-02-07 | Eastman Chemical Company | Coprecipitation of cellulose esters with functional additives and compositions thus obtainable |
JP4027535B2 (en) | 1998-05-26 | 2007-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Powder containing fat-soluble drug |
NZ508645A (en) | 1998-06-05 | 2003-10-31 | Forbes Medi Tech Inc | Compositions comprising phytosterol and/or phytostanol having enhanced solubility and dispersability and the use of these compositions to lower serum cholesterol |
CN1272785A (en) | 1998-06-11 | 2000-11-08 | Em工业股份有限公司 | Micro-osmotic controlled drug delivery system |
KR100336090B1 (en) | 1998-06-27 | 2002-05-27 | 윤승원 | Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof |
US6894171B1 (en) | 1998-07-20 | 2005-05-17 | Abbott Laboratories | Polymorph of a pharmaceutical |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US20010021372A1 (en) | 1998-08-18 | 2001-09-13 | Tore Omtveit | Apparatus having partially gold-plated surface |
DE19839276A1 (en) | 1998-08-28 | 2000-03-02 | Basf Ag | Process for the preparation of solid dosage forms |
DE19840256A1 (en) | 1998-09-03 | 2000-03-09 | Basf Ag | Widely applicable, continuous method for preparing coated solid dosage forms, comprises extruding mixture of drug and thermoplastic binder then applying coating composition in liquid or vapor form |
DE19841244A1 (en) | 1998-09-09 | 2000-03-16 | Knoll Ag | Method and device for making tablets |
DE19842753A1 (en) | 1998-09-18 | 2000-03-23 | Bayer Ag | Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose |
DE19842914A1 (en) | 1998-09-18 | 2000-03-23 | Basf Ag | Test system to characterize the compatibility of biologically active substances and polyvinylpyrrolidone |
DE19843904A1 (en) | 1998-09-24 | 2000-03-30 | Basf Ag | Solid dosage form for prolonged slow release of e.g. drugs, plant treatment agents, or food or feed additives, containing copolymer of N-vinyl-lactam, methyl methacrylate and further monomer(s) as binder |
US20040013613A1 (en) | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
DE19847618A1 (en) | 1998-10-15 | 2000-04-20 | Basf Ag | Production of solid dosage forms, used for e.g. pharmaceuticals or insecticides, by preparation of plastic mixture from polymeric binder and active agent under controlled conditions |
US6502135B1 (en) | 1998-10-30 | 2002-12-31 | Science Applications International Corporation | Agile network protocol for secure communications with assured system availability |
DE19853985A1 (en) | 1998-11-23 | 2000-05-25 | Basf Ag | Producing solid dosage form, using molding calender of two cylinders with specific surface structures, avoids problems of misalignment of upper and lower halves of the product |
DE19855440A1 (en) | 1998-12-01 | 2000-06-08 | Basf Ag | Process for the production of solid dosage forms by melt extrusion |
DE19856147A1 (en) | 1998-12-04 | 2000-06-08 | Knoll Ag | Divisible solid dosage forms and methods for their preparation |
DE19856432A1 (en) | 1998-12-08 | 2000-06-15 | Basf Ag | Nanoparticulate core-shell systems and their use in pharmaceutical and cosmetic preparations |
AT407111B (en) | 1998-12-22 | 2000-12-27 | Gergely Dr & Co | SUGAR- AND / OR SUGAR-ALCOHOLIC MATRIX MATERIAL AND METHOD FOR THE PRODUCTION THEREOF |
WO2000040220A1 (en) | 1999-01-06 | 2000-07-13 | Korea Research Institute Of Chemical Technology | Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same |
DE19901383A1 (en) | 1999-01-15 | 2000-07-20 | Knoll Ag | Process for the preparation of different solid dosage forms |
EP1027887B1 (en) | 1999-02-10 | 2008-08-13 | Pfizer Products Inc. | Matrix controlled release device |
ATE400252T1 (en) | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | PHARMACEUTICAL SOLID DISPERSIONS |
US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
US6440946B1 (en) | 1999-02-25 | 2002-08-27 | Takeda Chemical Industries, Ltd. | Multiple-agents-binding compound, production and use thereof |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DE19911097A1 (en) | 1999-03-12 | 2000-09-14 | Basf Ag | Process for the preparation of solid dosage forms containing cyclodextrin |
CN1156461C (en) | 1999-03-24 | 2004-07-07 | R·P·希拉技术股份有限公司 | Improved aqueous solubility pharmaceutical formulations |
DE19913606A1 (en) | 1999-03-25 | 2000-09-28 | Basf Ag | Powdery solubilization aids for solid pharmaceutical dosage forms |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
ES2432691T3 (en) | 1999-04-23 | 2013-12-04 | Leo Pharma A/S | Pharmaceutical composition for dermal use comprising calcipotril and betamethasone for the treatment of psoriasis |
FR2793689B1 (en) | 1999-05-19 | 2001-08-24 | Pf Medicament | TRANSDERMAL DEVICE FOR THE ADMINISTRATION OF TESTOSTERONE OR A DERIVATIVE THEREOF |
US7919119B2 (en) | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6465011B2 (en) | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
KR100815412B1 (en) | 1999-06-04 | 2008-03-20 | 아보트 러보러터리즈 | Improved pharmaceutical formulations |
NL1012300C2 (en) | 1999-06-11 | 2000-12-12 | Rijksuniversiteit | Stabilizer for pharmaceuticals. |
DE19929361A1 (en) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanically stable pharmaceutical dosage forms containing liquid or semi-solid surface-active substances |
FR2795326B1 (en) | 1999-06-28 | 2001-08-31 | Adir | SOLID THERMOFORMABLE PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
DE19930454A1 (en) | 1999-07-02 | 2001-01-04 | Knoll Ag | Solid paroxetine-containing preparations |
DE19934610A1 (en) | 1999-07-23 | 2001-01-25 | Bayer Ag | Rapid-release extrudates containing low viscosity hydroxypropylcellulose, useful for formulating plant protecting agents and oral pharmaceutical and veterinary compositions |
US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
DE19943501A1 (en) | 1999-09-10 | 2001-03-15 | Basf Ag | Underwater granulation of melts containing active ingredients |
SE9903236D0 (en) | 1999-09-10 | 1999-09-10 | Astra Ab | Method of obtaining microparticles |
DE19945982A1 (en) | 1999-09-24 | 2001-03-29 | Knoll Ag | Velocity-determined particles |
IL148801A0 (en) | 1999-09-24 | 2002-09-12 | Janssen Pharmaceutica Nv | Antiviral compositions |
WO2001022939A1 (en) | 1999-09-29 | 2001-04-05 | Fmc Corporation | Hydrolyzed cellulose granulations of salts of drugs |
DE19949897A1 (en) | 1999-10-15 | 2001-04-19 | Rainer Rogasch | Shaped article, e.g. in stick form, for controlled release of drugs in wounds or body cavities, comprising hydrophilic outer phase, lipophilic inner phase and drug, e.g. antibiotic |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US6372259B1 (en) | 1999-11-10 | 2002-04-16 | University Of Iowa Research Foundation | Palatable, sustained release drug granules |
CA2390092C (en) | 1999-11-12 | 2009-07-14 | Abbott Laboratories | Solid dispersion pharmaceutical formulations |
US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
CA2359945C (en) | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
DE19958007A1 (en) | 1999-12-02 | 2001-06-07 | Roehm Gmbh | Injection molding process for (meth) acrylate copolymers with tertiary ammonium groups |
DE19960494A1 (en) | 1999-12-15 | 2001-06-21 | Knoll Ag | Device and method for producing solid active substance-containing forms |
DE19961334A1 (en) | 1999-12-17 | 2001-06-21 | Roehm Gmbh | Injection molding process for neutral and acid group-containing (meth) acrylate copolymers |
EP1712222A3 (en) | 1999-12-23 | 2012-06-20 | Pfizer Products Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
OA12128A (en) | 1999-12-23 | 2006-05-05 | Pfizer Prod Inc | Hydrogel-driven drug dosage form. |
ES2398643T3 (en) | 1999-12-23 | 2013-03-20 | Mayne Pharma International Pty Ltd. | Enhanced pharmaceutical compositions for sparingly soluble drugs |
DE10000792A1 (en) | 2000-01-11 | 2001-07-19 | Bernhard C Lippold | Formulations of active substances in the form of a solid dispersion |
US7029700B2 (en) | 2000-01-14 | 2006-04-18 | Brown University Research Foundation | Micronized freeze-dried particles |
PT2269591T (en) | 2000-01-19 | 2018-07-09 | Abbvie Inc | Improved pharmaceutical formulations |
JP2001217428A (en) | 2000-01-25 | 2001-08-10 | Samsung Electronics Co Ltd | Low temperature polycrystalline silicon type thin film transistor and its manufacturing method |
GB0003782D0 (en) | 2000-02-17 | 2000-04-05 | Dumex Ltd As | Process |
GB0005016D0 (en) | 2000-03-01 | 2000-04-26 | Jumik Technologies Limited | PVA-Containing compositions |
DK1263413T3 (en) | 2000-03-09 | 2006-09-11 | Univ Ohio State Res Found | Process for preparing solid dispersions |
UY26615A1 (en) | 2000-03-16 | 2001-10-25 | Pfizer Prod Inc | GLUCOGEN PHOSPHORYLASE INHIBITOR. |
DE10013289A1 (en) | 2000-03-17 | 2001-09-20 | Knoll Ag | Storage-stable formulations containing diuretic torasemide, are solids or semi-solids containing the active agent in non-crystalline form, e.g. as solid solution in vinyl pyrrolidone polymer matrix |
DE10015479A1 (en) | 2000-03-29 | 2001-10-11 | Basf Ag | Solid oral dosage forms with delayed release of active ingredient and high mechanical stability |
US6608198B2 (en) | 2000-03-30 | 2003-08-19 | Abbott Laboratories | Crystalline pharmaceutical |
MY128296A (en) | 2000-03-30 | 2007-01-31 | Abbott Lab | Crystalline pharmaceutical |
GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
DE10021539C1 (en) | 2000-05-03 | 2002-02-28 | Henkel Kgaa | Device for spray drying solvent-containing compositions |
KR20010107754A (en) | 2000-05-26 | 2001-12-07 | 민경윤 | Process for preparing rapidly disintegrating tablet for oral administration |
DE10026699A1 (en) | 2000-05-30 | 2001-12-06 | Basf Ag | Formulation based on heparin, glycosaminoglycan or heparinoid and use of the formulation and the formulation base |
DE10026698A1 (en) | 2000-05-30 | 2001-12-06 | Basf Ag | Self-emulsifying active ingredient formulation and use of this formulation |
DE10029201A1 (en) | 2000-06-19 | 2001-12-20 | Basf Ag | Retarded release oral dosage form, obtained by granulating mixture containing active agent and polyvinyl acetate-polyvinyl pyrrolidone mixture below the melting temperature |
WO2002002081A1 (en) | 2000-07-05 | 2002-01-10 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
US20100010101A1 (en) | 2000-07-05 | 2010-01-14 | Capricorn Pharma, Inc. | Rapid-Melt Compositions and Methods of Making Same |
IT1318618B1 (en) | 2000-07-10 | 2003-08-27 | A C R Applied Coating Res S A | QUICK RELEASE BIOADHESIVE MICROSPHERES FOR SUBLINGUAL ADMINISTRATION OF ACTIVE INGREDIENTS. |
AU2001289653A1 (en) | 2000-07-14 | 2002-01-30 | Universiteit Gent | Composite solid shaped articles for the controlled delivery of biologically active ingredients |
DE10038571A1 (en) | 2000-08-03 | 2002-02-14 | Knoll Ag | Compositions and dosage forms for use in the oral cavity in the treatment of mycoses |
EP1308156A4 (en) | 2000-08-11 | 2009-07-15 | Eisai R&D Man Co Ltd | Drug-containing solid dispersion having improved solubility |
US6372905B1 (en) | 2000-08-31 | 2002-04-16 | Abbott Laboratories | Processes and intermediates for preparing retroviral protease inhibitors |
BR0108433A (en) | 2000-09-05 | 2006-06-06 | Abbott Lab | flavoring systems for pharmaceutical compositions and methods for making such compositions |
DE10046541A1 (en) | 2000-09-19 | 2002-03-28 | Knoll Ag | Oral dosage form useful as nutritional supplement or medicament comprises solid dispersion of ubiquinone in thermoplastic matrix |
FR2814366A1 (en) | 2000-09-22 | 2002-03-29 | Rhodia Chimie Sa | PROCESS FOR GRANULATING ACTIVE MATERIALS BY LOW PRESSURE EXTRUSION FOR OBTAINING DIRECTLY COMPRESSIBLE GRANULES |
DE60143704D1 (en) | 2000-09-25 | 2011-02-03 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING A MEDICAL SOLID DISPERSION |
CA2423484A1 (en) | 2000-09-27 | 2002-04-04 | Verion Inc. | Instant water dissolvable encapsulate and process |
WO2002035991A2 (en) | 2000-10-30 | 2002-05-10 | The Board Of Regents, The University Of Texas System | Spherical particles produced by a hot-melt extrusion/spheronization process |
GB0026593D0 (en) | 2000-10-31 | 2000-12-13 | Quadrant Holdings Cambridge | Derivatised carbohydrates and their use in solid delivery systems |
AU2002212102A1 (en) | 2000-11-08 | 2002-05-21 | Aeromatic-Fielder Ag | A process for production of particles for pharmaceutical compositions having increased bioavailability |
CA2428784A1 (en) | 2000-11-09 | 2002-05-16 | Astrazeneca Ab | Oral pharmaceutical composition containing a block copolymer |
GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
US6733781B2 (en) | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
GB0029843D0 (en) | 2000-12-07 | 2001-01-24 | Univ Belfast | Drug delivery system |
US7883721B2 (en) | 2001-01-30 | 2011-02-08 | Smithkline Beecham Limited | Pharmaceutical formulation |
US20050175687A1 (en) | 2001-01-30 | 2005-08-11 | Mcallister Stephen M. | Pharmaceutical formulations |
US7842308B2 (en) | 2001-01-30 | 2010-11-30 | Smithkline Beecham Limited | Pharmaceutical formulation |
ATE324871T1 (en) | 2001-02-13 | 2006-06-15 | Astrazeneca Ab | NEW MODIFIED RELEASE FORMULATION |
GB0104752D0 (en) | 2001-02-27 | 2001-04-18 | Astrazeneca Ab | Pharmaceutical compositions |
US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
CA2445967A1 (en) | 2001-05-01 | 2002-11-07 | Abbott Laboratories | Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents |
HU229938B1 (en) | 2001-05-03 | 2015-01-28 | Hoffmann La Roche | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
AR033711A1 (en) | 2001-05-09 | 2004-01-07 | Novartis Ag | PHARMACEUTICAL COMPOSITIONS |
ATE429431T1 (en) | 2001-05-11 | 2009-05-15 | Tibotec Pharm Ltd | 2-AMINO-BENZOXAZOLE SUPHONAMIDES AS BROAD-SPECTR HIV PROTEASE INHIBITORS |
CA2448438A1 (en) | 2001-05-25 | 2002-12-05 | Abbott Laboratories | Soft elastic capsules comprising ritonavir and/or lopinavir |
CA2447693A1 (en) | 2001-05-31 | 2002-12-05 | Cima Labs Inc. | Taste-masking of highly water-soluble drugs |
DE10127134A1 (en) | 2001-06-05 | 2002-12-12 | Roehm Gmbh | Production of injection molded shaped articles, especially for retarded drug release, by blending (meth)acrylate copolymer with plasticizer and other additives, degassing and molding |
US6730319B2 (en) | 2001-06-06 | 2004-05-04 | Hoffmann-La Roche Inc. | Pharmaceutical compositions having depressed melting points |
US20030212102A1 (en) | 2001-06-12 | 2003-11-13 | Koretke Todd W | Novel solid dispersion compositions |
NZ529490A (en) | 2001-06-22 | 2005-08-26 | Pfizer Prod Inc | Pharmaceutical compositions of adsorbates of amorphous drug |
BR0210520A (en) | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Pharmaceutical compositions of amorphous drug dispersions mixed with polymers |
CA2450748A1 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
WO2003000292A1 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers |
JP2004534812A (en) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | Pharmaceutical composition of dispersion of drug and neutral polymer |
EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
ITMI20011337A1 (en) | 2001-06-26 | 2002-12-26 | Farmatron Ltd | ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF THE ACTIVE SUBSTANCE |
ITMI20011338A1 (en) | 2001-06-26 | 2002-12-26 | Farmatron Ltd | ORAL PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE OF THE ACTIVE INGREDIENT |
AU2002325192B2 (en) | 2001-07-06 | 2008-05-22 | Veloxis Pharmaceuticals, Inc. | Controlled agglomeration |
CA2453157A1 (en) | 2001-07-09 | 2003-01-23 | Shell Canada Limited | Inhibiting scale deposition in oilfield tubulars |
DE10133570C1 (en) | 2001-07-13 | 2002-09-05 | Octel Corp | Purification of water, especially ground water, contaminated with lead alkyls, especially lead methyl and lead ethyl, comprises passing water through organic cation exchanger |
US20030044474A1 (en) | 2001-08-03 | 2003-03-06 | Shaklee Corporation | High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability |
FR2828380B1 (en) | 2001-08-10 | 2005-07-29 | Fontarome | COMPOSITE COMPOSITE COMPOSITION CONTAINING AROMATIC SUBSTANCES AND / OR VOLATILE NON-AROMATIC SUBSTANCES AND / OR SENSITIVE TO EXTERNAL AGENTS, AND PROCESS FOR PRODUCING THE SAME |
JP4644397B2 (en) | 2001-09-05 | 2011-03-02 | 信越化学工業株式会社 | Method for producing pharmaceutical solid preparation containing poorly soluble drug |
DE60224293T2 (en) | 2001-09-21 | 2008-12-11 | Egalet A/S | SOLID DISPERSIONS WITH CONTROLLED RELEASE OF CARVEDILOL |
US20040213848A1 (en) | 2001-09-28 | 2004-10-28 | Shun-Por Li | Modified release dosage forms |
US6982094B2 (en) | 2001-09-28 | 2006-01-03 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
US7122143B2 (en) | 2001-09-28 | 2006-10-17 | Mcneil-Ppc, Inc. | Methods for manufacturing dosage forms |
DE10151290A1 (en) | 2001-10-22 | 2003-04-30 | Roehm Gmbh | Process for the preparation of active ingredient-containing pellets |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
JP2005509001A (en) | 2001-10-29 | 2005-04-07 | セリクス, インコーポレイテッド | Three-dimensional suspension printing of dosage forms |
US7491407B2 (en) | 2001-10-31 | 2009-02-17 | North Carolina State University | Fiber-based nano drug delivery systems (NDDS) |
JP2003146869A (en) | 2001-11-14 | 2003-05-21 | Scg:Kk | Intraoral disintegration type solid preparation and its production |
US6524606B1 (en) | 2001-11-16 | 2003-02-25 | Ap Pharma, Inc. | Bioerodible polyorthoesters containing amine groups |
US20030129250A1 (en) | 2001-11-20 | 2003-07-10 | Advanced Inhalation Research Inc. | Particulate compositions for improving solubility of poorly soluble agents |
US7179488B2 (en) | 2001-11-29 | 2007-02-20 | Bob Sherwood | Process for co-spray drying liquid herbal extracts with dry silicified MCC |
EP1509204A4 (en) | 2001-11-29 | 2005-07-13 | Rettenmaier & Soehne Gmbh & Co | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
US20030206978A1 (en) | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
US20030147965A1 (en) | 2001-12-10 | 2003-08-07 | Spherics, Inc. | Methods and products useful in the formation and isolation of microparticles |
US20050202090A1 (en) | 2002-01-03 | 2005-09-15 | Clarke Allan J. | Novel pharmaceutical dosage forms and method for producing same |
ES2305434T3 (en) | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | FRAMACEUTICAL COMPOSITIONS OF AMORPHIC DISPERSIONS OF PHARMACS AND MATERIALS FORMING LIPOFIL MICROPHASES. |
BR0307333A (en) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Methods for preparing homogeneous dispersions of atomized amorphous solid drugs using a spray drying system |
RS67304A (en) | 2002-02-01 | 2006-10-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
RU2004123621A (en) | 2002-02-01 | 2005-04-10 | Пфайзер Продактс Инк. (Us) | MEDICINAL FORMS WITH IMMEDIATE RELEASE CONTAINING SOLID DISPERSIONS OF MEDICINES |
AR038681A1 (en) | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | ORAL FORMULATION OF SOLID SOLUTION OF A POVERLY SOLUBLE ACTIVE SUBSTANCE IN WATER |
DE10208344A1 (en) | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Melt extrusion of active ingredient salts |
GB0205253D0 (en) | 2002-03-06 | 2002-04-17 | Univ Gent | Immediate release pharmaceutical granule compositions and a continuous process for making them |
US20050163852A1 (en) | 2002-03-07 | 2005-07-28 | Massimo Bresciani | Process for loading and thermodynamically activating drungs on polymers by means of supercritical fluids |
ES2292655T3 (en) | 2002-03-15 | 2008-03-16 | Alrise Biosystems Gmbh | MICROPARTICLES AND PROCEDURE FOR PREPARATION. |
DE10213242A1 (en) | 2002-03-25 | 2003-10-16 | Abbott Gmbh & Co Kg | Test system for evaluating the compatibility of biologically active substances with copolymers |
DE10213977A1 (en) | 2002-03-28 | 2003-10-16 | Krauss Maffei Kunststofftech | Process for the production of molded articles containing active ingredients |
ATE344665T1 (en) | 2002-04-04 | 2006-11-15 | Cadila Pharmaceuticals Ltd | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIRETROVIRAL PROTEASE INHIBITOR WITH IMPROVED BIOAVAILABILITY |
LT2425821T (en) | 2002-04-05 | 2017-07-25 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
BR0309340A (en) | 2002-04-19 | 2005-03-08 | Novartis Ag | Materials, their preparation and use |
US20030203027A1 (en) | 2002-04-26 | 2003-10-30 | Ethicon, Inc. | Coating technique for deposition of drug substance on a substrate |
US7205413B2 (en) | 2002-05-03 | 2007-04-17 | Transform Pharmaceuticals, Inc. | Solvates and polymorphs of ritonavir and methods of making and using the same |
JP2005532313A (en) | 2002-05-07 | 2005-10-27 | コントロール・デリバリー・システムズ・インコーポレイテッド | Method for forming drug delivery device |
GB0214013D0 (en) | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
EP1515703A1 (en) | 2002-06-21 | 2005-03-23 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
AU2003260239A1 (en) | 2002-06-26 | 2004-01-19 | Tuo Jin | Solid dosage forms for rapid dissolution of poorly soluble drugs |
AR039744A1 (en) | 2002-06-26 | 2005-03-09 | Alza Corp | METHODS AND DOSAGE FORMS TO INCREASE THE SOLUBILITY OF PHARMACOS COMPOSITIONS FOR CONTROLLED ADMINISTRATION |
US7407670B2 (en) | 2002-07-04 | 2008-08-05 | Janssen Pharmaceutica, N.V. | Solid dispersions comprising two different polymer matrixes |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
TW200410714A (en) | 2002-08-07 | 2004-07-01 | Smithkline Beecham Corp | Electrospun amorphous pharmaceutical compositions |
EP2111856A3 (en) | 2002-08-12 | 2014-09-10 | Bend Research, Inc. | Pharmaceutical compositions of semi-ordered drugs and polymers |
WO2004014450A1 (en) | 2002-08-13 | 2004-02-19 | Medtronic, Inc. | Active agent delivery system including a hydrophobic cellulose derivate |
CA2495172A1 (en) | 2002-08-13 | 2004-02-19 | Medtronic, Inc. | Active agent delivery systems, medical devices, and methods |
CA2498207C (en) | 2002-09-11 | 2012-03-13 | Elan Pharma International Ltd. | Gel-stabilized nanoparticulate active agent compositions |
US20040062778A1 (en) | 2002-09-26 | 2004-04-01 | Adi Shefer | Surface dissolution and/or bulk erosion controlled release compositions and devices |
DE10247037A1 (en) | 2002-10-09 | 2004-04-22 | Abbott Gmbh & Co. Kg | Solid, rapid release dosage form, especially for sparingly soluble drugs, obtained by forming and cooling softened, shapable mixture of crosslinked non-thermoplastic carrier, adjuvant and active agent |
EP1569620A4 (en) | 2002-10-30 | 2006-03-22 | Spherics Inc | Nanoparticulate bioactive agents |
FR2846557B1 (en) | 2002-10-30 | 2007-06-08 | Statice Sante | IMPLANTABLE STRUCTURE FOR PROLONGED AND CONTROLLED RELEASE OF AN ACTIVE INGREDIENT |
DE10250711A1 (en) | 2002-10-31 | 2004-05-19 | Degussa Ag | Pharmaceutical and cosmetic preparations |
AU2002350719A1 (en) | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
US7670627B2 (en) | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
CN100473378C (en) | 2002-12-17 | 2009-04-01 | 阿伯特有限及两合公司 | Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof |
US6872799B2 (en) | 2002-12-18 | 2005-03-29 | Ethicon, Inc. | Functionalized polymers for medical applications |
US20040121003A1 (en) | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
EP1575563B1 (en) | 2002-12-19 | 2007-02-14 | Pharmacia Corporation | Non-hygroscopic formulation comprising a hydroscopic drug |
ITMI20022748A1 (en) | 2002-12-23 | 2004-06-24 | Eurand Int | STABILIZED SOLID DISPERSIONS OF DRUG IN AN ORGANIC CAREER AND PROCEDURE FOR THEIR PREPARATION. |
WO2004062643A1 (en) | 2003-01-14 | 2004-07-29 | Lifecycle Pharma A/S | Dry dispersions |
DE10304403A1 (en) | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Process for the preparation of an oral dosage form with immediate disintegration and drug release |
US20040258752A1 (en) | 2003-01-31 | 2004-12-23 | Paruthi Manoj Kumar | Taste masking pharmaceutical composition and process for its preparation |
WO2004069138A2 (en) | 2003-02-03 | 2004-08-19 | Novartis Ag | Pharmaceutical formulation |
US6931888B2 (en) | 2003-02-07 | 2005-08-23 | Ferro Corporation | Lyophilization method and apparatus for producing particles |
US20040156894A1 (en) | 2003-02-07 | 2004-08-12 | Grother Leon Paul | Use of edible acids in fast-dispersing pharmaceutical solid dosage forms |
US20060286169A1 (en) | 2003-02-13 | 2006-12-21 | Phares Pharmaceutical Research N.V. | Lipophilic compositions |
GB0304726D0 (en) | 2003-03-01 | 2003-04-02 | Ardana Bioscience Ltd | New Process |
GB0305941D0 (en) | 2003-03-14 | 2003-04-23 | Camurus Ab | Composition |
US20040185170A1 (en) | 2003-03-21 | 2004-09-23 | Shubha Chungi | Method for coating drug-containing particles and formulations and dosage units formed therefrom |
ATE399538T1 (en) | 2003-03-26 | 2008-07-15 | Egalet As | MATRIX PREPARATIONS FOR THE CONTROLLED PRESENTATION OF MEDICINAL MEDICINAL PRODUCTS |
US20040208928A1 (en) | 2003-04-15 | 2004-10-21 | Animal Technology Institute Taiwan | Method for preparing an orally administrable formulation for controlled release |
CA2523218A1 (en) | 2003-04-22 | 2004-11-04 | Dr. Reddy's Laboratories Limited | Oral pharmaceutical formulations of acid-labile active ingredients and process for making same |
GB0310300D0 (en) | 2003-05-06 | 2003-06-11 | Univ Belfast | Nanocomposite drug delivery composition |
WO2004100883A2 (en) | 2003-05-06 | 2004-11-25 | Bpsi Holdings, Inc. | Method for preparing thermoformed compositions containing acrylic polymer binders, pharmaceutual dosage forms and methods of preparing the same |
JP2004339162A (en) | 2003-05-16 | 2004-12-02 | Shin Etsu Chem Co Ltd | Pharmaceutical solid preparation containing sparingly soluble medicine and method for producing the same |
EP1479381A1 (en) | 2003-05-19 | 2004-11-24 | Euro-Celtique S.A. | Pharmaceutical dosage form comprising a solid solution |
US7862834B2 (en) | 2003-05-28 | 2011-01-04 | Novartis Pharma Ag | Pharmaceutical formulation comprising a water-insoluble active agent |
US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
DE10325989A1 (en) | 2003-06-07 | 2005-01-05 | Glatt Gmbh | Process for the preparation of and resulting micropellets and their use |
WO2004112755A1 (en) | 2003-06-18 | 2004-12-29 | John Michael Newton | Controlled release devices with lumens |
US20040265378A1 (en) | 2003-06-25 | 2004-12-30 | Yingxu Peng | Method and compositions for producing granules containing high concentrations of biologically active substances |
RS20060009A (en) | 2003-07-11 | 2008-06-05 | F.Hoffmann-La Roche Ag., | Saquinavir mesylate oral dosage form |
DE10332160A1 (en) | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multiparticulate dosage form containing mucoadhesively formulated peptide or protein active substances, and a method for producing the dosage form |
TW200526274A (en) | 2003-07-21 | 2005-08-16 | Smithkline Beecham Plc | Pharmaceutical formulations |
BR0302523A (en) | 2003-07-23 | 2005-04-05 | Cristalia Prod Quimicos Farm | Stable pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical composition for administration of hiv protease inhibitors |
US7645474B1 (en) | 2003-07-31 | 2010-01-12 | Advanced Cardiovascular Systems, Inc. | Method and system of purifying polymers for use with implantable medical devices |
US7785512B1 (en) | 2003-07-31 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices |
WO2005011635A2 (en) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
US9522377B2 (en) | 2003-08-04 | 2016-12-20 | Camurus Ab | Method for improving the properties of amphiphile particles |
CL2004001884A1 (en) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS. |
JP2007501224A (en) | 2003-08-05 | 2007-01-25 | フジ フォト フィルム ビー.ブイ. | Use of recombinant or synthetic gelatin-like proteins as stabilizers in lyophilized pharmaceutical compositions |
DE10339197A1 (en) | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried amorphous powder with low residual moisture and good storage stability |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US20070122482A1 (en) | 2003-10-03 | 2007-05-31 | Per Holm | Method for preparing modified release pharmaceutical compositions |
KR20060121909A (en) | 2003-10-08 | 2006-11-29 | 버텍스 파마슈티칼스 인코포레이티드 | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
US8349361B2 (en) | 2003-10-15 | 2013-01-08 | Fuji Chemical Industry Co., Ltd. | Composition for rapid disintegrating tablet in oral cavity |
KR101159617B1 (en) | 2003-10-15 | 2012-06-27 | 후지카가쿠고교가부시키가이샤 | Tablet quickly disintegrating in oral cavity |
EP1677827B1 (en) | 2003-10-27 | 2008-12-10 | Vertex Pharmaceuticals Incorporated | Combinations for hcv treatment |
US7413690B1 (en) | 2003-10-29 | 2008-08-19 | The University Of Mississippi | Process and apparatus for producing spherical pellets using molten solid matrices |
CN1878540B (en) | 2003-12-15 | 2012-02-29 | 科学与工业研究委员会 | Taste masked pharmaceutical composition comprising pH sensitive polymer |
WO2005115343A2 (en) | 2004-05-28 | 2005-12-08 | Abbott Gmbh & Co. Kg | Formulation obtained from a powder mixture comprising an inorganic pigment |
US20050281876A1 (en) | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
DE102004040104A1 (en) | 2004-08-18 | 2006-02-23 | Basf Ag | Use of amphiphilic copolymers as solubilizers |
GB0501835D0 (en) | 2005-01-28 | 2005-03-09 | Unilever Plc | Improvements relating to spray dried compositions |
US20090104269A1 (en) | 2005-02-11 | 2009-04-23 | Brian Graham | Nanoformulations |
EP1855655A2 (en) | 2005-02-25 | 2007-11-21 | F. Hoffmann-Roche AG | Tablets with improved drug substance dispersibility |
MX2007014587A (en) | 2005-06-03 | 2008-02-05 | Horizon Science Pty Ltd | Delivery systems. |
WO2007002041A2 (en) | 2005-06-21 | 2007-01-04 | Foster Corporation | Drug-filled polymer films |
JP2009502841A (en) | 2005-07-26 | 2009-01-29 | グラクソ グループ リミテッド | Encapsulation of lipid-based formulations in enteric polymers |
PT1912626T (en) | 2005-08-08 | 2016-07-20 | Abbvie Deutschland | Dosage forms with improved bioavailability |
WO2007017452A2 (en) | 2005-08-11 | 2007-02-15 | Basf Se | N-vinylcaprolactam-based copolymers and the use thereof as solubilizers |
EP1942875B1 (en) | 2005-08-24 | 2015-08-12 | Rubicon Research Private Limited | Controlled release formulation |
US20070077305A1 (en) | 2005-10-03 | 2007-04-05 | Le Tien C | Biocompatible polymeric matrix and preparation thereof |
WO2007050631A2 (en) | 2005-10-25 | 2007-05-03 | Cima Labs Inc. | Dosage form with coated active |
ITMI20052461A1 (en) | 2005-12-22 | 2007-06-23 | Univ Degli Studi Milano | MICROPARTELAR SYSTEMS FOR ORAL ADMINISTRATION OF BIOLOGICALLY ACTIVE SUBSTANCES |
JP2009526040A (en) | 2006-02-10 | 2009-07-16 | エル・ジー ハウスホールド アンド ヘルスケア リミティッド | Simultaneously dissolving and gelling tablet type oral hygiene composition |
WO2007111866A2 (en) | 2006-03-23 | 2007-10-04 | Schering Corporation | Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto |
US7771632B2 (en) | 2006-05-15 | 2010-08-10 | American Leistritz Extruder Corp. | Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets |
JP2009540032A (en) | 2006-06-07 | 2009-11-19 | ビーエーエスエフ ソシエタス・ヨーロピア | Use of vinyl acetate-sulfonate copolymer as a solubilizer for compounds with low water solubility |
US8343548B2 (en) | 2006-08-08 | 2013-01-01 | Shin-Etsu Chemical Co., Ltd. | Solid dosage form comprising solid dispersion |
US7923026B2 (en) | 2006-10-20 | 2011-04-12 | Solvay Pharmaceuticals B.V. | Embedded micellar nanoparticles |
WO2008067164A2 (en) | 2006-11-15 | 2008-06-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
US20100062073A1 (en) | 2006-11-29 | 2010-03-11 | Ronald Arthur Beyerinck | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein |
DE102007009242A1 (en) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets with enteric-coated matix |
US20100204425A1 (en) | 2007-07-26 | 2010-08-12 | Basf Se | Process for preparing copolymers obtained by graft polymerization in solution and based on polyethers in solid form |
EP2022805A3 (en) | 2007-08-03 | 2009-02-25 | Basf Se | Copolymers based on N-vinyllactams and olefins as their use as solubilizers for slightly water-soluble compounds |
MY153890A (en) | 2007-10-11 | 2015-04-15 | Philip Morris Products Sa | Smokeless tobacco product |
WO2009113522A1 (en) | 2008-03-11 | 2009-09-17 | あすか製薬株式会社 | Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both |
AR071375A1 (en) | 2008-04-22 | 2010-06-16 | Solvay Pharm Gmbh | FORMULATIONS FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF DEFICIENT PERMEABILITY, PREPARATION AND PRODUCT PROCESS |
WO2010017053A1 (en) | 2008-08-06 | 2010-02-11 | Isp Investments, Inc. | Solid excipient compositions |
GB0815852D0 (en) | 2008-09-01 | 2008-10-08 | Unilever Plc | Improvements relating to pharmaceutical compositions |
US20100068268A1 (en) | 2008-09-15 | 2010-03-18 | Miloud Rahmouni | Starch-based microparticles for the release of agents disposed therein |
JP2012506904A (en) | 2008-10-28 | 2012-03-22 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | Mesoporous material excipients for poorly water soluble ingredients |
US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
US20100166857A1 (en) | 2008-12-30 | 2010-07-01 | Dong Yan | Pharmaceutical dosage forms and methods of manufacturing same |
CN101444494B (en) | 2008-12-31 | 2011-03-30 | 江苏大学 | Efficient long-acting sustained-release preparation of slightly soluble medicine and preparation method thereof |
AU2010211220B2 (en) | 2009-02-06 | 2013-08-01 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
EP2311435A1 (en) | 2009-10-07 | 2011-04-20 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer |
WO2011090724A2 (en) | 2009-12-29 | 2011-07-28 | Impax Laboratories, Inc. | Gastroretentive solid oral dosage forms with lipid-based low-density excipient |
CN102821754B (en) | 2010-03-26 | 2014-06-18 | 陶氏环球技术有限责任公司 | Multilayer melt-extruded film |
US20110288181A1 (en) | 2010-05-21 | 2011-11-24 | Basf Se | Preparations of biologically active substances with enlarged surface based on amphiphilic copolymers |
CN103153343B (en) | 2010-06-14 | 2015-02-11 | 陶氏环球技术有限责任公司 | Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution |
-
2004
- 2004-08-25 US US10/925,442 patent/US8025899B2/en not_active Expired - Fee Related
-
2007
- 2007-07-03 US US11/773,185 patent/US20070249643A1/en not_active Abandoned
-
2010
- 2010-09-13 US US12/880,766 patent/US8333990B2/en not_active Expired - Fee Related
- 2010-09-13 US US12/880,781 patent/US8309613B2/en not_active Expired - Fee Related
-
2011
- 2011-09-22 US US13/240,119 patent/US8399015B2/en not_active Expired - Fee Related
-
2012
- 2012-04-18 US US13/449,958 patent/US8268349B2/en active Active
- 2012-11-12 US US13/674,799 patent/US8691878B2/en not_active Expired - Fee Related
-
2014
- 2014-02-26 US US14/190,618 patent/US20140179721A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6599528B1 (en) * | 1999-03-25 | 2003-07-29 | Abbott Gmbh & Co. Kg | Mechanically stable pharmaceutical presentations form containing liquid or semisolid surface-active substances |
US6579521B2 (en) * | 2000-10-20 | 2003-06-17 | Chiron Corporation | Methods of therapy for HIV infection |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9107830B2 (en) | 1999-11-12 | 2015-08-18 | Abbvie, Inc. | Inhibitors of crystallization in a solid dispersion |
US8691878B2 (en) | 2003-08-28 | 2014-04-08 | Abbvie Inc. | Solid pharmaceutical dosage form |
US8268349B2 (en) | 2003-08-28 | 2012-09-18 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8399015B2 (en) | 2003-08-28 | 2013-03-19 | Abbvie Inc. | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8309613B2 (en) | 2003-08-28 | 2012-11-13 | Abbvie Inc. | Solid pharmaceutical dosage form |
US8333990B2 (en) | 2003-08-28 | 2012-12-18 | Abbott Laboratories | Solid pharmaceutical dosage form |
EP2641593A3 (en) * | 2008-02-28 | 2013-11-20 | AbbVie Inc. | Tablets |
EP2641593A2 (en) * | 2008-02-28 | 2013-09-25 | AbbVie Inc. | Tablets |
US20100021540A1 (en) * | 2008-02-28 | 2010-01-28 | Abbott Laboratories | Tablets and Preparation Thereof |
EP2444070A1 (en) * | 2008-02-28 | 2012-04-25 | Abbott Laboratories | Tablets |
WO2009108865A2 (en) * | 2008-02-28 | 2009-09-03 | Abbott Laboratories | Tablets and preparation thereof |
WO2009108865A3 (en) * | 2008-02-28 | 2009-11-19 | Abbott Laboratories | Tablets and preparation thereof |
EP3272337A3 (en) * | 2008-02-28 | 2018-02-14 | AbbVie Inc. | Tablets |
RU2711359C2 (en) * | 2009-06-08 | 2020-01-16 | Эббви Дойчланд Гмбх Унд Ко. Кг | Pharmaceutical dosage form for oral administration of bcl-2 family inhibitor |
EP2819668A4 (en) * | 2012-03-01 | 2015-07-29 | Hetero Research Foundation | Ritonavir compositions |
WO2019219823A1 (en) * | 2018-05-18 | 2019-11-21 | Pharmaceutical Oriented Services Ltd. | Solid dispersion containing ritonavir |
Also Published As
Publication number | Publication date |
---|---|
US8333990B2 (en) | 2012-12-18 |
US20130072508A1 (en) | 2013-03-21 |
US8268349B2 (en) | 2012-09-18 |
US8399015B2 (en) | 2013-03-19 |
US20110008430A1 (en) | 2011-01-13 |
US8309613B2 (en) | 2012-11-13 |
US20120022089A1 (en) | 2012-01-26 |
US20120202858A1 (en) | 2012-08-09 |
US8691878B2 (en) | 2014-04-08 |
US8025899B2 (en) | 2011-09-27 |
US20110015216A1 (en) | 2011-01-20 |
US20140179721A1 (en) | 2014-06-26 |
US20050084529A1 (en) | 2005-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8691878B2 (en) | Solid pharmaceutical dosage form | |
EP2258345B1 (en) | Solid pharmaceutical dosage form comprising an HIV protease inhibitor solid dispersion | |
AU2013201423B2 (en) | Solid pharmaceutical dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |